<!DOCTYPE html>
<html xmlns="https://www.w3.org/1999/xhtml" class="fa-events-icons-ready gr__clinicaltrials_gov" lang="en">

<div id="main-content">

<div class="indent2">
        	<h1 class="solo_record">Efficacy and Safety Study of Elagolix in Women With Endometriosis</h1>

  <div class="row">
    <div class="column left">
      <div class="usa-alert usa-alert-warning" style="clear:both;margin:2ex 2em;">
        <table>
          <tbody><tr>
            <td style="width:5%">
              <img src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20in%20Women%20With%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/warning.png" style="width:1.3em;" alt="">
            </td>
            <td>
              The safety and scientific validity of this study is the 
responsibility of the study sponsor and investigators. Listing a study 
does not mean it has been evaluated by the U.S. Federal Government.
                            Read our <a href="https://clinicaltrials.gov/ct2/about-site/disclaimer">disclaimer</a> for details.
            </td>
          </tr>
        </tbody></table>
      </div>      </div> 
<!--
  <div style="float:right;margin-right:4em">ClinicalTrials.gov Identifier: NCT00973973</div>
-->
    <div class="column right">
  <table style="width:90%">
  <tbody><tr><td>ClinicalTrials.gov Identifier: NCT00973973</td>
  </tr>
  <tr><td>
      
       
              <div class="not-recruiting-status">
                        <span style="display:inline;" class="term" data-term="recruitment status" title="Show definition" tabindex="0">Recruitment Status <i class="fa fa-info-circle term" aria-hidden="true" data-term="recruitment status" style="border-bottom-style:none;" title="Show definition" tabindex="0"></i></span>: 
                    Completed
                  
                
  <div style="font-size:inherit">
  <span style="display:inline;" class="term" data-term="first posted" title="Show definition" tabindex="0">First Posted <i class="fa fa-info-circle term" aria-hidden="true" data-term="first posted" style="border-bottom-style:none;" title="Show definition" tabindex="0"></i></span>: September 9, 2009</div>
      <div style="font-size:inherit">
    <span style="display:inline;" class="term" data-term="results first posted" title="Show definition" tabindex="0">Results First Posted <i class="fa fa-info-circle term" aria-hidden="true" data-term="results first posted" style="border-bottom-style:none;" title="Show definition" tabindex="0"></i></span>: September 26, 2018</div>
    <div style="font-size:inherit">
  <span style="display:inline;" class="term" data-term="last update posted" title="Show definition" tabindex="0">Last Update Posted <i class="fa fa-info-circle term" aria-hidden="true" data-term="last update posted" style="border-bottom-style:none;" title="Show definition" tabindex="0"></i></span>: September 26, 2018</div>

  
      </div>
  </td>
  </tr>
  </tbody></table>
  </div>
  </div>


                <div class="info-title">Sponsor:</div>
                <div class="info-text" id="sponsor"> AbbVie </div>

                              <div class="info-title">Information provided by (Responsible Party):</div>
                <div class="info-text" id="responsibleparty">AbbVie</div>
              	</div>
<br>


<div id="tabs">
    <ul id="tab-links">
		<li id="full-text"><a href="https://clinicaltrials.gov/ct2/show/study/NCT00973973?sect=X01256">Study Details</a></li>
		<li id="tabular"><a href="https://clinicaltrials.gov/ct2/show/record/NCT00973973?sect=X01256">Tabular View</a></li>
  					<li id="results" class="current"> Study Results</li>
				<li id="disclaimer"><a title="Disclaimer - opens new window" href="https://clinicaltrials.gov/ct2/about-site/disclaimer" onclick="openNewWindow('/ct2/about-site/disclaimer'); return false">Disclaimer</a></li>
		<li id="howtoread"><a title="How to Read a Study Record - opens new window" href="https://clinicaltrials.gov/ct2/help/how-read-study" onclick="openNewWindow('/ct2/help/how-read-study'); return false">How to Read a Study Record</a></li>
    </ul>
</div>  <!--
<div style="background-color:#f6f6f6;margin-top:5.0ex;padding-bottom:1.5ex;"> </div>
-->

  <div id="tab-body">
  <div class="indent2" style="background-color:white;">
  <!-- Title section -->
  <div class="indent3" style="text-align:center;">
    
  
  <table class="data_table" style="margin:3ex 0;" width="80%" cellspacing="0" cellpadding="5" border="1">

        <tbody><tr>
      <th class="header3 pale_banner_color" style="text-align:right;white-space:nowrap;">Study Type: </th>
      <td class="body3" style="text-align:left;">Interventional</td>
    </tr>
    
        <tr>
      <th class="header3 pale_banner_color" style="text-align:right;white-space:nowrap;">Study Design: </th>
      <td class="body3" style="text-align:left;">Allocation:&nbsp;Randomized;
 &nbsp; Intervention&nbsp;Model:&nbsp;Parallel&nbsp;Assignment; &nbsp; 
Masking:&nbsp;Quadruple&nbsp;(Participant,&nbsp;Care&nbsp;Provider,&nbsp;Investigator,&nbsp;Outcomes&nbsp;Assessor);
 &nbsp; Primary&nbsp;Purpose:&nbsp;Treatment</td>
    </tr>
    
        <tr>
      <th class="header3 pale_banner_color" style="text-align:right;white-space:nowrap;">
         Condition:       </th>
      <td class="body3" style="text-align:left;white-space:nowrap;">
                Endometriosis, Pain<br>
              </td>
    </tr>
    
        <tr>
      <th class="header3 pale_banner_color" style="text-align:right;white-space:nowrap;">
        Interventions:       </th>
      <td class="body3" style="text-align:left;white-space:nowrap;">
                Drug: Placebo<br>
                Drug: Elagolix<br>
              </td>
    </tr>
    
  </tbody></table>

  
  </div>
  
<!-- participant flow section -->
<div class="indent1">

  <br>
  <img src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20in%20Women%20With%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/triangle.gif" alt=""><span class="header2">&nbsp; Participant Flow</span>

  <a name="part" id="part"></a>
  <div class="header3 indent2">

        <div style="margin-top:1.0ex;">      
      <a title="Hide participant flow" href="https://clinicaltrials.gov/ct2/show/results/NCT00973973?sect=X1256#part">
        <img style="float:left" src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20in%20Women%20With%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/minus.gif" alt="" border="0"> &nbsp; Hide Participant Flow
      </a>
    </div>

    <br>
    <span class="header3">Recruitment Details</span>
    <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
      <tbody><tr>
        <th class="header3 bold_participant_color" style="text-align:left;">
          Key information relevant to the recruitment process for the
          overall study, such as dates of the recruitment period and locations
        </th>
      </tr>
      <tr>
        <td class="body3 pale_participant_color" style="vertical-align:top;">
                      Participants were enrolled at 37 centers in the United States.
                  </td>
      </tr>
    </tbody></table>

    <br>
    <span class="header3">Pre-Assignment Details</span>
    <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
      <tbody><tr>
        <th class="header3 bold_participant_color" style="text-align:left;">
          Significant events and approaches for the overall study
          following participant enrollment, but prior to group assignment
        </th>
      </tr>
      <tr>
        <td class="body3 pale_participant_color" style="vertical-align:top;">
                      The study consisted of up to 8 weeks of screening 
with data collection to establish baseline pain, an 8-week double-blind 
placebo-controlled treatment period, a 16-week open-label treatment 
period with all patients receiving elagolix 150 mg once per day, and a 
6-week posttreatment follow-up period.
                  </td>
      </tr>
    </tbody></table>

    
    <br>
        
      
            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_participant_color">&nbsp;</th>
      <th class="header3 bold_participant_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_participant_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_participant_color" style="vertical-align:top;">
                          Participants received placebo orally once a 
day for 8 weeks during the double-blind treatment period and switched to
 receive 150 mg elagolix for 16 weeks during the open-label treatment 
period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_participant_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_participant_color" style="vertical-align:top;">
                          Participants received 150 mg elagolix orally 
once a day for 8 weeks during the double-blind treatment period and 
continued to receive 150 mg elagolix for 16 additional weeks during the 
open-label treatment period.
                      </td>
        </tr>
      </tbody></table>

      <br>
              <span class="header3">Participant Flow for 2 periods<br><br></span>
      
                    
        <span class="header3">Period 1: &nbsp; Double-blind Treatment Phase (Weeks 1-8)</span>
        <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0">
          <tbody><tr>
                          <th class="brt bold_participant_color" style="max-width:50%">&nbsp;</th>
                                                      <th class="header3 brt bold_participant_color" style="max-width:20%; text-align:center;">
                              &nbsp; 
                Placebo
              </th>
                                          <th class="header3 brt bold_participant_color" style="max-width:20%; text-align:center;">
                              &nbsp; 
                Elagolix 150 mg
              </th>
                      </tr>
                
                
                          <tr>
                <th class="header3 brt bold_participant_color" style="text-align:left;">
                  STARTED&nbsp;                                  </th>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;69&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;68&nbsp;                  </td>
                              </tr>
              
                            
                          <tr>
                <th class="header3 brt bold_participant_color" style="text-align:left;">
                  Received Study Drug&nbsp;                                  </th>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;69&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;68&nbsp;                  </td>
                              </tr>
              
                            
                          <tr>
                <th class="header3 brt bold_participant_color" style="text-align:left;">
                  COMPLETED&nbsp;                                  </th>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;63&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;60&nbsp;                  </td>
                              </tr>
              
                            
                          <tr>
                <th class="header3 brt bold_participant_color" style="text-align:left;">
                  NOT COMPLETED&nbsp;                                  </th>
                                                      <td class="header3 brt pale_participant_color" style="text-align:center;">
                      &nbsp;6&nbsp;                    </td>
                                      <td class="header3 brt pale_participant_color" style="text-align:center;">
                      &nbsp;8&nbsp;                    </td>
                                                </tr>
                              <tr>
                  <td class="header3 br bold_participant_color" style="padding-left:2em;">
                    Adverse Event&nbsp;                                      </td>
                                                            <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 1&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 3&nbsp;                      </td>
                                                      </tr>
                              <tr>
                  <td class="header3 br bold_participant_color" style="padding-left:2em;">
                    Protocol Deviation&nbsp;                                      </td>
                                                            <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 1&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                                      </tr>
                              <tr>
                  <td class="header3 br bold_participant_color" style="padding-left:2em;">
                    Withdrawal by Subject&nbsp;                                      </td>
                                                            <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 1&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 3&nbsp;                      </td>
                                                      </tr>
                              <tr>
                  <td class="header3 br bold_participant_color" style="padding-left:2em;">
                    Lack of Efficacy&nbsp;                                      </td>
                                                            <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 1&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                                      </tr>
                              <tr>
                  <td class="header3 br bold_participant_color" style="padding-left:2em;">
                    Lost to Follow-up&nbsp;                                      </td>
                                                            <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 1&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 1&nbsp;                      </td>
                                                      </tr>
                              <tr>
                  <td class="header3 br bold_participant_color" style="padding-left:2em;">
                    Sponsor/Investigator Decision&nbsp;                                      </td>
                                                            <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 1&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 1&nbsp;                      </td>
                                                      </tr>
                                            </tbody></table>
      
                <br>
        
                    
        <span class="header3">Period 2: &nbsp; Open-label Treatment Phase (Weeks 8-24)</span>
        <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0">
          <tbody><tr>
                          <th class="brt bold_participant_color" style="max-width:50%">&nbsp;</th>
                                                      <th class="header3 brt bold_participant_color" style="max-width:20%; text-align:center;">
                              &nbsp; 
                Placebo
              </th>
                                          <th class="header3 brt bold_participant_color" style="max-width:20%; text-align:center;">
                              &nbsp; 
                Elagolix 150 mg
              </th>
                      </tr>
                
                
                          <tr>
                <th class="header3 brt bold_participant_color" style="text-align:left;">
                  STARTED&nbsp;                                  </th>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;63&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;60&nbsp;                  </td>
                              </tr>
              
                            
                          <tr>
                <th class="header3 brt bold_participant_color" style="text-align:left;">
                  COMPLETED&nbsp;                                  </th>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;57&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;55&nbsp;                  </td>
                              </tr>
              
                            
                          <tr>
                <th class="header3 brt bold_participant_color" style="text-align:left;">
                  NOT COMPLETED&nbsp;                                  </th>
                                                      <td class="header3 brt pale_participant_color" style="text-align:center;">
                      &nbsp;6&nbsp;                    </td>
                                      <td class="header3 brt pale_participant_color" style="text-align:center;">
                      &nbsp;5&nbsp;                    </td>
                                                </tr>
                              <tr>
                  <td class="header3 br bold_participant_color" style="padding-left:2em;">
                    Adverse Event&nbsp;                                      </td>
                                                            <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 1&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 2&nbsp;                      </td>
                                                      </tr>
                              <tr>
                  <td class="header3 br bold_participant_color" style="padding-left:2em;">
                    Protocol Deviation&nbsp;                                      </td>
                                                            <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 1&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                                      </tr>
                              <tr>
                  <td class="header3 br bold_participant_color" style="padding-left:2em;">
                    Noncompliance&nbsp;                                      </td>
                                                            <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 1&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                                      </tr>
                              <tr>
                  <td class="header3 br bold_participant_color" style="padding-left:2em;">
                    Withdrawal by Subject&nbsp;                                      </td>
                                                            <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 1&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 3&nbsp;                      </td>
                                                      </tr>
                              <tr>
                  <td class="header3 br bold_participant_color" style="padding-left:2em;">
                    Lost to Follow-up&nbsp;                                      </td>
                                                            <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 1&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                                      </tr>
                              <tr>
                  <td class="header3 br bold_participant_color" style="padding-left:2em;">
                    Sponsor/Investigator Decision&nbsp;                                      </td>
                                                            <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 1&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                                      </tr>
                                            </tbody></table>
      
                <br>
        
              </div>
</div>
  
<!-- baseline section -->
<br>
<div class="indent1">

  <br>
  <img src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20in%20Women%20With%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/triangle.gif" alt=""><span class="header2">&nbsp; Baseline Characteristics</span>

  <a name="base" id="base"></a>
  <div class="header3 indent2">

        <div style="margin-top:1.0ex;">
      <a title="Hide baseline characteristics" href="https://clinicaltrials.gov/ct2/show/results/NCT00973973?sect=X0256#base">
        <img style="float:left" src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20in%20Women%20With%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/minus.gif" alt="" border="0"> &nbsp; Hide Baseline Characteristics
      </a>
    </div>

    <br>
    <span class="header3">Population Description</span>
    <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
      <tbody><tr>
        <th class="header3 bold_baseline_color" style="text-align:left;">
          Explanation of how the number of participants for analysis was determined.
          Includes whether analysis was per protocol, intention to treat, or another method.
          Also provides relevant details such as imputation technique, as appropriate.
        </th>
      </tr>
      <tr>
        <td class="body3 pale_baseline_color" style="vertical-align:top;">
                      No text entered.
                  </td>
      </tr>
    </tbody></table>

    <br>
    
            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_baseline_color">&nbsp;</th>
      <th class="header3 bold_baseline_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_baseline_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_baseline_color" style="vertical-align:top;">
                          Participants received placebo orally once a 
day for 8 weeks during the double-blind treatment period and switched to
 receive 150 mg elagolix for 16 weeks during the open-label treatment 
period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_baseline_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_baseline_color" style="vertical-align:top;">
                          Participants received 150 mg elagolix orally 
once a day for 8 weeks during the double-blind treatment period and 
continued to receive 150 mg elagolix for 16 additional weeks during the 
open-label treatment period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_baseline_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Total</th>
          <td class="body3 pale_baseline_color" style="vertical-align:top;">
                          Total of all reporting groups
                      </td>
        </tr>
      </tbody></table>
      
      <br>
            
          
          
    
      <span class="header3">Baseline Measures</span>
      <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0">
        <tbody><tr>
          <th class="brt bold_baseline_color" style="max-width:50%">&nbsp;</th>
                      <th class="header3 brt bold_baseline_color" style="max-width:20%;text-align:center;">
              &nbsp;Placebo&nbsp;
            </th>
                      <th class="header3 brt bold_baseline_color" style="max-width:20%;text-align:center;">
              &nbsp;Elagolix 150 mg&nbsp;
            </th>
                      <th class="header3 brt bold_baseline_color" style="max-width:20%;text-align:center;">
              &nbsp;Total&nbsp;
            </th>
                  </tr>
    
            
                      <tr>
              <th class="header3 brt bold_baseline_color" style="text-align:left;">
                Overall Participants Analyzed&nbsp;                <br><span class="body3">[Units:&nbsp;Participants]<br></span>               </th>
                              <td class="header3 brt pale_baseline_color" style="text-align:center;">
                                      &nbsp;69&nbsp;                                  </td>
                              <td class="header3 brt pale_baseline_color" style="text-align:center;">
                                      &nbsp;68&nbsp;                                  </td>
                              <td class="header3 brt pale_baseline_color" style="text-align:center;">
                                      &nbsp;137&nbsp;                                  </td>
                          </tr>
            
              
                                    <tr>
                <td class="brt" colspan="1000" style="padding:2px 2px;">
              </td></tr>
                                  
                      <tr>
              <th class="header3 brt bold_baseline_color" style="text-align:left;">
                Age&nbsp;                <br><span class="body3">[Units:&nbsp;Years]<br>Mean (Standard Deviation)</span>               </th>
                              <td class="header3 brt pale_baseline_color" style="text-align:center;">
                                                            
&nbsp;33.0&nbsp;&nbsp;(0.9)&nbsp;                                       
               </td>
                              <td class="header3 brt pale_baseline_color" style="text-align:center;">
                                                            
&nbsp;32.8&nbsp;&nbsp;(0.7)&nbsp;                                       
               </td>
                              <td class="header3 brt pale_baseline_color" style="text-align:center;">
                                                            
&nbsp;32.9&nbsp;&nbsp;(0.6)&nbsp;                                       
               </td>
                          </tr>
            
              
                                    <tr>
                <td class="brt" colspan="1000" style="padding:2px 2px;">
              </td></tr>
                                  
                      <tr>
              <th class="header3 brt bold_baseline_color" style="text-align:left;">
                Sex: Female, Male&nbsp;                <br><span class="body3">[Units:&nbsp;Participants]<br>Count of Participants</span>               </th>
                                                <td class="brt pale_baseline_color">&nbsp;</td>
                                  <td class="brt pale_baseline_color">&nbsp;</td>
                                  <td class="brt pale_baseline_color">&nbsp;</td>
                                          </tr>
                          <tr>
                <td class="header3 br bold_baseline_color" style="padding-left:2em;">
                  Female&nbsp;                                  </td>
                                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 69<span class="body3"> 100.0%</span>&nbsp;                                          </td>
                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 68<span class="body3"> 100.0%</span>&nbsp;                                          </td>
                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 137<span class="body3"> 100.0%</span>&nbsp;                                          </td>
                                                </tr>
                                        <tr>
                <td class="header3 br bold_baseline_color" style="padding-left:2em;">
                  Male&nbsp;                                  </td>
                                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 0<span class="body3">   0.0%</span>&nbsp;                                          </td>
                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 0<span class="body3">   0.0%</span>&nbsp;                                          </td>
                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 0<span class="body3">   0.0%</span>&nbsp;                                          </td>
                                                </tr>
                                        
                                    <tr>
                <td class="brt" colspan="1000" style="padding:2px 2px;">
              </td></tr>
                                  
                      <tr>
              <th class="header3 brt bold_baseline_color" style="text-align:left;">
                Race/Ethnicity, Customized&nbsp;                <br><span class="body3">[Units:&nbsp;Participants]<br>Count of Participants</span>               </th>
                                                <td class="brt pale_baseline_color">&nbsp;</td>
                                  <td class="brt pale_baseline_color">&nbsp;</td>
                                  <td class="brt pale_baseline_color">&nbsp;</td>
                                          </tr>
                          <tr>
                <td class="header3 br bold_baseline_color" style="padding-left:2em;">
                  American Indian or Alaska Native&nbsp;                                  </td>
                                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 0<span class="body3">   0.0%</span>&nbsp;                                          </td>
                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 2<span class="body3">   2.9%</span>&nbsp;                                          </td>
                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 2<span class="body3">   1.5%</span>&nbsp;                                          </td>
                                                </tr>
                                        <tr>
                <td class="header3 br bold_baseline_color" style="padding-left:2em;">
                  Asian&nbsp;                                  </td>
                                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 0<span class="body3">   0.0%</span>&nbsp;                                          </td>
                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 0<span class="body3">   0.0%</span>&nbsp;                                          </td>
                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 0<span class="body3">   0.0%</span>&nbsp;                                          </td>
                                                </tr>
                                        <tr>
                <td class="header3 br bold_baseline_color" style="padding-left:2em;">
                  Black&nbsp;                                  </td>
                                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 7<span class="body3">  10.1%</span>&nbsp;                                          </td>
                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 6<span class="body3">   8.8%</span>&nbsp;                                          </td>
                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 13<span class="body3">   9.5%</span>&nbsp;                                          </td>
                                                </tr>
                                        <tr>
                <td class="header3 br bold_baseline_color" style="padding-left:2em;">
                  White&nbsp;                                  </td>
                                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 57<span class="body3">  82.6%</span>&nbsp;                                          </td>
                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 55<span class="body3">  80.9%</span>&nbsp;                                          </td>
                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 112<span class="body3">  81.8%</span>&nbsp;                                          </td>
                                                </tr>
                                        <tr>
                <td class="header3 br bold_baseline_color" style="padding-left:2em;">
                  Hispanic&nbsp;                                  </td>
                                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 5<span class="body3">   7.2%</span>&nbsp;                                          </td>
                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 5<span class="body3">   7.4%</span>&nbsp;                                          </td>
                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 10<span class="body3">   7.3%</span>&nbsp;                                          </td>
                                                </tr>
                                        <tr>
                <td class="header3 br bold_baseline_color" style="padding-left:2em;">
                  Native Hawaiian or Other Pacific Islander&nbsp;                                  </td>
                                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 0<span class="body3">   0.0%</span>&nbsp;                                          </td>
                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 0<span class="body3">   0.0%</span>&nbsp;                                          </td>
                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 0<span class="body3">   0.0%</span>&nbsp;                                          </td>
                                                </tr>
                                        
                                    <tr>
                <td class="brt" colspan="1000" style="padding:2px 2px;">
              </td></tr>
                                    </tbody></table>
      
      
      
        </div>
</div>
  
<!-- outcome measures section -->
<br>
<div class="indent1">

  <br>
  <img src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20in%20Women%20With%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/triangle.gif" alt=""><span class="header2">&nbsp; Outcome Measures</span>
  <a name="all" id="all"></a>
  <div class="header3 indent2">

            <div style="margin-top:1.0ex;">
      <a title="Hide all outcome measures" href="https://clinicaltrials.gov/ct2/show/results/NCT00973973?sect=X0156#all">
        <img style="float:left" src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20in%20Women%20With%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/minus.gif" alt="" border="0"> &nbsp; Hide All Outcome Measures
      </a>
    </div>
    
                  <a name="outcome1" id="outcome1"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">1.&nbsp; Primary: &nbsp; </td>
            <td>Change From Baseline in the Monthly Mean Dysmenorrhea 
Score During the Double-blind Treatment Phase &nbsp; [ Time Frame: 
Baseline and Weeks 4 and 8 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Primary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From Baseline in the Monthly Mean Dysmenorrhea Score During the Double-blind Treatment Phase</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">Participants
 assessed dysmenorrhea (pain during menstruation) and its impact on 
their daily activities at approximately the same time each day of their 
period in an electronic diary (e-Diary) according to the following 
response options:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">0 = No discomfort</li>
    <li style="margin-top:0.7ex;">1 = Mild discomfort but I was easily able to do the things I usually do</li>
    <li style="margin-top:0.7ex;">2 = Moderate discomfort or pain that made it difficult to do some of the things I usually do</li>
    <li style="margin-top:0.7ex;">3 = Severe pain that made it difficult to do the things I usually do.</li>
  </ul>
  <p style="margin-top:0ex; margin-bottom:1ex;">The monthly mean dysmenorrhea score is the average of the daily values reported during the 4 weeks prior to each visit.</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and Weeks 4 and 8 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 10 evaluable
 e-Diary reports during the double-blind period (intent-to-treat 
population). The analysis includes participants with non-missing data at
 each time point.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo orally once a 
day for 8 weeks during the double-blind treatment period and switched to
 receive 150 mg elagolix for 16 weeks during the open-label treatment 
period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received 150 mg elagolix orally 
once a day for 8 weeks during the double-blind treatment period and 
continued to receive 150 mg elagolix for 16 additional weeks during the 
open-label treatment period.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;66&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;66&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline in the Monthly Mean 
Dysmenorrhea Score During the Double-blind Treatment Phase&nbsp;        
                <br><span class="body3">[Units:&nbsp;Units&nbsp;on&nbsp;a&nbsp;scale]<br>Least Squares Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 4&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;66&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;66&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 4&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.24&nbsp;&nbsp;(0.076)&nbsp;
                                                                        
                              </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.49&nbsp;&nbsp;(0.076)&nbsp;
                                                                        
                              </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 8&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;64&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;64&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 8&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.37&nbsp;&nbsp;(0.107)&nbsp;
                                                                        
                              </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-1.13&nbsp;&nbsp;(0.107)&nbsp;
                                                                        
                              </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                                                <br>
                  <span class="header3">Statistical Analysis 1 for Change From Baseline in the Monthly Mean Dysmenorrhea Score During the Double-blind Treatment Phase</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">All groups</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">ANCOVA</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0262</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.24</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.45 to -0.03</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.107)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Comparison of Change from Baseline at Week 4
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          Analysis of 
covariance (ANCOVA) model including baseline value as a covariate.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 2 for Change From Baseline in the Monthly Mean Dysmenorrhea Score During the Double-blind Treatment Phase</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">All groups</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">ANCOVA</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">&lt; 0.0001</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.76</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-1.06 to -0.46</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.152)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Comparison of change from baseline at week 8
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          Analysis of 
covariance (ANCOVA) model, including baseline value as a covariate.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                            <br>
              <br>
                              </div>
              <a name="outcome2" id="outcome2"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">2.&nbsp; Primary: &nbsp; </td>
            <td>Change From Baseline in the Monthly Mean Dysmenorrhea 
Score During the Open-label and Posttreatment Phases &nbsp; [ Time 
Frame: Baseline and Weeks 12, 16, 20, 24, and 30 (6 weeks posttreatment)
 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Primary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From Baseline in the Monthly Mean Dysmenorrhea Score During the Open-label and Posttreatment Phases</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">Participants
 assessed dysmenorrhea (pain during menstruation) and its impact on 
their daily activities at approximately the same time each day of their 
period in an electronic diary (e-Diary) according to the following 
response options:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">0 = No discomfort</li>
    <li style="margin-top:0.7ex;">1 = Mild discomfort but I was easily able to do the things I usually do</li>
    <li style="margin-top:0.7ex;">2 = Moderate discomfort or pain that made it difficult to do some of the things I usually do</li>
    <li style="margin-top:0.7ex;">3 = Severe pain that made it difficult to do the things I usually do.</li>
  </ul>
  <p style="margin-top:0ex; margin-bottom:1ex;">The monthly mean 
dysmenorrhea score is the average of the daily values reported during 
the 4 weeks prior to each visit, except for the week 30 value which is 
based on 6 weeks of data.</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and Weeks 12, 16, 20, 24, and 30 (6 weeks posttreatment) &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 10 evaluable
 e-Diary reports during the double-blind period (intent-to-treat 
population) with data on or after Week 12. The analysis includes 
participants with non-missing data at each time point.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo orally once a 
day for 8 weeks during the double-blind treatment period and switched to
 receive 150 mg elagolix for 16 weeks during the open-label treatment 
period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received 150 mg elagolix orally 
once a day for 8 weeks during the double-blind treatment period and 
continued to receive 150 mg elagolix for 16 additional weeks during the 
open-label treatment period.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;61&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;60&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline in the Monthly Mean 
Dysmenorrhea Score During the Open-label and Posttreatment Phases&nbsp; 
                       <br><span class="body3">[Units:&nbsp;Units&nbsp;on&nbsp;a&nbsp;scale]<br>Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 12&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;61&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;60&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 12&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.768&nbsp;&nbsp;(0.118)&nbsp;                                   
                                                                   </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-1.060&nbsp;&nbsp;(0.130)&nbsp;                                   
                                                                   </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 16&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;61&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;59&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 16&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-1.325&nbsp;&nbsp;(0.112)&nbsp;                                   
                                                                   </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-1.022&nbsp;&nbsp;(0.137)&nbsp;                                   
                                                                   </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 20&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 20&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-1.026&nbsp;&nbsp;(0.119)&nbsp;                                   
                                                                   </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.991&nbsp;&nbsp;(0.121)&nbsp;                                   
                                                                   </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 24&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 24&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-1.282&nbsp;&nbsp;(0.118)&nbsp;                                   
                                                                   </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-1.372&nbsp;&nbsp;(0.132)&nbsp;                                   
                                                                   </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 30&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;55&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;55&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 30&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.547&nbsp;&nbsp;(0.104)&nbsp;                                   
                                                                   </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.534&nbsp;&nbsp;(0.102)&nbsp;                                   
                                                                   </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                              <span class="header3">No statistical 
analysis provided for Change From Baseline in the Monthly Mean 
Dysmenorrhea Score During the Open-label and Posttreatment Phases</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome3" id="outcome3"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">3.&nbsp; Primary: &nbsp; </td>
            <td>Change From Baseline in the Monthly Mean Non-menstrual 
Pelvic Pain Score During the Double-Blind Treatment Phase &nbsp; [ Time 
Frame: Baseline and weeks 4 and 8 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Primary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From Baseline in the Monthly Mean Non-menstrual Pelvic Pain Score During the Double-Blind Treatment Phase</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">Participants
 assessed their pelvic pain not related to menses and its impact on 
their daily activities at approximately the same time each day they were
 not having their period in an e-Diary according to the following 
response options:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">0 = No discomfort</li>
    <li style="margin-top:0.7ex;">1 = Mild discomfort but I was easily able to do the things I usually do</li>
    <li style="margin-top:0.7ex;">2 = Moderate discomfort or pain that made it difficult to do some of the things I usually do</li>
    <li style="margin-top:0.7ex;">3 = Severe pain that made it difficult to do the things I usually do.</li>
  </ul>
  <p style="margin-top:0ex; margin-bottom:1ex;">The monthly mean 
non-menstrual pelvic pain score is the average of the daily values 
reported during the 4 weeks prior to each visit.</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and weeks 4 and 8 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 10 evaluable
 e-Diary reports during the double-blind period (intent-to-treat 
population). The analysis includes participants with non-missing data at
 each time point.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo orally once a 
day for 8 weeks during the double-blind treatment period and switched to
 receive 150 mg elagolix for 16 weeks during the open-label treatment 
period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received 150 mg elagolix orally 
once a day for 8 weeks during the double-blind treatment period and 
continued to receive 150 mg elagolix for 16 additional weeks during the 
open-label treatment period.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;66&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;66&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline in the Monthly Mean 
Non-menstrual Pelvic Pain Score During the Double-Blind Treatment 
Phase&nbsp;                        <br><span class="body3">[Units:&nbsp;Units&nbsp;on&nbsp;a&nbsp;scale]<br>Least Squares Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 4&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;66&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;66&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 4&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.05&nbsp;&nbsp;(0.061)&nbsp;
                                                                        
                              </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.26&nbsp;&nbsp;(0.061)&nbsp;
                                                                        
                              </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 8&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;64&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;64&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 8&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.19&nbsp;&nbsp;(0.071)&nbsp;
                                                                        
                              </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.47&nbsp;&nbsp;(0.071)&nbsp;
                                                                        
                              </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                                                <br>
                  <span class="header3">Statistical Analysis 1 for 
Change From Baseline in the Monthly Mean Non-menstrual Pelvic Pain Score
 During the Double-Blind Treatment Phase</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">All groups</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">ANCOVA</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0163</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.21</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.38 to -0.04</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.086)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Comparison of change from baseline at week 4
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          ANCOVA model including baseline value as a covariate.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 2 for 
Change From Baseline in the Monthly Mean Non-menstrual Pelvic Pain Score
 During the Double-Blind Treatment Phase</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">All groups</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">ANCOVA</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0066</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.28</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.48 to -0.08</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.101)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Comparison of change from baseline at week 8
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          ANCOVA model including baseline value as a covariate.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                            <br>
              <br>
                              </div>
              <a name="outcome4" id="outcome4"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">4.&nbsp; Primary: &nbsp; </td>
            <td>Change From Baseline in the Monthly Mean Non-menstrual 
Pelvic Pain Score During the Open-label and Posttreatment Phases &nbsp; [
 Time Frame: Baseline and Weeks 12, 16, 20, 24, and 30 (6 weeks 
posttreatment) ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Primary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From Baseline in the Monthly Mean Non-menstrual Pelvic Pain Score During the Open-label and Posttreatment Phases</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">Participants
 assessed their pelvic pain not related to menses and its impact on 
their daily activities at approximately the same time each day they were
 not having their period in an e-Diary according to the following 
response options:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">0 = No discomfort</li>
    <li style="margin-top:0.7ex;">1 = Mild discomfort but I was easily able to do the things I usually do</li>
    <li style="margin-top:0.7ex;">2 = Moderate discomfort or pain that made it difficult to do some of the things I usually do</li>
    <li style="margin-top:0.7ex;">3 = Severe pain that made it difficult to do the things I usually do.</li>
  </ul>
  <p style="margin-top:0ex; margin-bottom:1ex;">The monthly mean 
non-menstrual pelvic pain score is the average of the daily values 
reported during the 4 weeks prior to each visit, except for the week 30 
value which is based on 6 weeks of data.</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and Weeks 12, 16, 20, 24, and 30 (6 weeks posttreatment) &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 10 evaluable
 e-Diary reports during the double-blind period (intent-to-treat 
population) with data on or after Week 12. The analysis includes 
participants with non-missing data at each time point.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo orally once a 
day for 8 weeks during the double-blind treatment period and switched to
 receive 150 mg elagolix for 16 weeks during the open-label treatment 
period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received 150 mg elagolix orally 
once a day for 8 weeks during the double-blind treatment period and 
continued to receive 150 mg elagolix for 16 additional weeks during the 
open-label treatment period.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;61&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;60&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline in the Monthly Mean 
Non-menstrual Pelvic Pain Score During the Open-label and Posttreatment 
Phases&nbsp;                        <br><span class="body3">[Units:&nbsp;Units&nbsp;on&nbsp;a&nbsp;scale]<br>Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 12&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;61&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;60&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 12&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.355&nbsp;&nbsp;(0.087)&nbsp;                                   
                                                                   </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.727&nbsp;&nbsp;(0.072)&nbsp;                                   
                                                                   </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 16&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;61&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;59&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 16&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.422&nbsp;&nbsp;(0.078)&nbsp;                                   
                                                                   </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.763&nbsp;&nbsp;(0.079)&nbsp;                                   
                                                                   </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 20&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 20&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.524&nbsp;&nbsp;(0.090)&nbsp;                                   
                                                                   </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.759&nbsp;&nbsp;(0.082)&nbsp;                                   
                                                                   </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 24&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 24&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.543&nbsp;&nbsp;(0.092)&nbsp;                                   
                                                                   </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.801&nbsp;&nbsp;(0.082)&nbsp;                                   
                                                                   </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 30&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;55&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;55&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 30&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.326&nbsp;&nbsp;(0.104)&nbsp;                                   
                                                                   </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.689&nbsp;&nbsp;(0.085)&nbsp;                                   
                                                                   </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                              <span class="header3">No statistical 
analysis provided for Change From Baseline in the Monthly Mean 
Non-menstrual Pelvic Pain Score During the Open-label and Posttreatment 
Phases</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome5" id="outcome5"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">5.&nbsp; Primary: &nbsp; </td>
            <td>Change From Baseline in the Monthly Mean Cumulative Pain
 Score During the Double-Blind Treatment Phase &nbsp; [ Time Frame: 
Baseline and weeks 4 and 8 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Primary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From Baseline in the Monthly Mean Cumulative Pain Score During the Double-Blind Treatment Phase</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">Participants
 assessed dysmenorrhea or non-menstrual pelvic pain at approximately the
 same time each day in an e-Diary according to the following:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">0 = No discomfort</li>
    <li style="margin-top:0.7ex;">1 = Mild discomfort but I was easily able to do the things I usually do</li>
    <li style="margin-top:0.7ex;">2 = Moderate discomfort or pain that made it difficult to do some of the things I usually do</li>
    <li style="margin-top:0.7ex;">3 = Severe pain that made it difficult to do the things I usually do.</li>
  </ul>
  <p style="margin-top:0ex; margin-bottom:1ex;">The monthly mean 
cumulative pain score is the average of the daily values for all days 
(menstrual and non-menstrual) reported during the 4 weeks prior to each 
visit.</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and weeks 4 and 8 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 10 evaluable
 e-Diary reports during the double-blind period (intent-to-treat 
population). The analysis includes participants with non-missing data at
 each time point.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo orally once a 
day for 8 weeks during the double-blind treatment period and switched to
 receive 150 mg elagolix for 16 weeks during the open-label treatment 
period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received 150 mg elagolix orally 
once a day for 8 weeks during the double-blind treatment period and 
continued to receive 150 mg elagolix for 16 additional weeks during the 
open-label treatment period.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;66&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;66&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline in the Monthly Mean 
Cumulative Pain Score During the Double-Blind Treatment Phase&nbsp;     
                   <br><span class="body3">[Units:&nbsp;Units&nbsp;on&nbsp;a&nbsp;scale]<br>Least Squares Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 4&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;66&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;66&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 4&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.11&nbsp;&nbsp;(0.058)&nbsp;
                                                                        
                              </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.32&nbsp;&nbsp;(0.058)&nbsp;
                                                                        
                              </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 8&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;64&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;64&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 8&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.21&nbsp;&nbsp;(0.070)&nbsp;
                                                                        
                              </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.55&nbsp;&nbsp;(0.070)&nbsp;
                                                                        
                              </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                                                <br>
                  <span class="header3">Statistical Analysis 1 for 
Change From Baseline in the Monthly Mean Cumulative Pain Score During 
the Double-Blind Treatment Phase</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">All groups</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">ANCOVA</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0089</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.22</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.38 to -0.06</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.082)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Comparison of change from baseline at week 4
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          ANCOVA model including baseline value as a covariate.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 2 for 
Change From Baseline in the Monthly Mean Cumulative Pain Score During 
the Double-Blind Treatment Phase</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">All groups</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">ANCOVA</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0011</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.33</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.53 to -0.14</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.100)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Comparison of change from baseline at week 8
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          ANCOVA model including baseline value as a covariate.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                            <br>
              <br>
                              </div>
              <a name="outcome6" id="outcome6"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">6.&nbsp; Primary: &nbsp; </td>
            <td>Change From Baseline in the Monthly Mean Cumulative Pain
 Score During the Open-label and Posttreatment Phases &nbsp; [ Time 
Frame: Baseline and Weeks 12, 16, 20, 24, and 30 (6 weeks posttreatment)
 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Primary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From Baseline in the Monthly Mean Cumulative Pain Score During the Open-label and Posttreatment Phases</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">Participants
 assessed dysmenorrhea or non-menstrual pelvic pain at approximately the
 same time each day in an e-Diary according to the following:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">0: No discomfort</li>
    <li style="margin-top:0.7ex;">1: Mild discomfort, I was easily able to do the things I usually do</li>
    <li style="margin-top:0.7ex;">2: Moderate discomfort or pain making it difficult to do some of the things I usually do</li>
    <li style="margin-top:0.7ex;">3: Severe pain making it difficult to do the things I usually do</li>
  </ul>
  <p style="margin-top:0ex; margin-bottom:1ex;">The monthly mean 
cumulative pain score is the average of the daily values for all days 
(menstrual and non-menstrual) reported during the 4 weeks prior to each 
visit, except for the week 30 value which is based on 6 weeks of data.</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and Weeks 12, 16, 20, 24, and 30 (6 weeks posttreatment) &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 10 evaluable
 e-Diary reports during the double-blind period (intent-to-treat 
population) with data on or after Week 12. The analysis includes 
participants with non-missing data at each time point.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo orally once a 
day for 8 weeks during the double-blind treatment period and switched to
 receive 150 mg elagolix for 16 weeks during the open-label treatment 
period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received 150 mg elagolix orally 
once a day for 8 weeks during the double-blind treatment period and 
continued to receive 150 mg elagolix for 16 additional weeks during the 
open-label treatment period.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;61&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;60&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline in the Monthly Mean 
Cumulative Pain Score During the Open-label and Posttreatment 
Phases&nbsp;                        <br><span class="body3">[Units:&nbsp;Units&nbsp;on&nbsp;a&nbsp;scale]<br>Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 12&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;61&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;60&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 12&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.433&nbsp;&nbsp;(0.082)&nbsp;                                   
                                                                   </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.781&nbsp;&nbsp;(0.070)&nbsp;                                   
                                                                   </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 16&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;61&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;59&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 16&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.530&nbsp;&nbsp;(0.072)&nbsp;                                   
                                                                   </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.793&nbsp;&nbsp;(0.083)&nbsp;                                   
                                                                   </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 20&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 20&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.615&nbsp;&nbsp;(0.085)&nbsp;                                   
                                                                   </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.798&nbsp;&nbsp;(0.081)&nbsp;                                   
                                                                   </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 24&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 24&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.655&nbsp;&nbsp;(0.088)&nbsp;                                   
                                                                   </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.878&nbsp;&nbsp;(0.082)&nbsp;                                   
                                                                   </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 30&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;55&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;55&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 30&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.374&nbsp;&nbsp;(0.095)&nbsp;                                   
                                                                   </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.666&nbsp;&nbsp;(0.085)&nbsp;                                   
                                                                   </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                              <span class="header3">No statistical 
analysis provided for Change From Baseline in the Monthly Mean 
Cumulative Pain Score During the Open-label and Posttreatment Phases</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome7" id="outcome7"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">7.&nbsp; Primary: &nbsp; </td>
            <td>Change From Baseline in the Monthly Mean Dyspareunia 
Score During the Double-Blind Treatment Phase &nbsp; [ Time Frame: 
Baseline and weeks 4 and 8 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Primary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From Baseline in the Monthly Mean Dyspareunia Score During the Double-Blind Treatment Phase</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">Participants
 assessed their dyspareunia (pain during sexual intercourse) at 
approximately the same time every day in an e-Diary according to the 
following response options:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">0 = Absent; No discomfort during sexual intercourse</li>
    <li style="margin-top:0.7ex;">1 = Mild; I was able to tolerate the discomfort during sexual intercourse</li>
    <li style="margin-top:0.7ex;">2 = Moderate; Intercourse was interrupted due to pain</li>
    <li style="margin-top:0.7ex;">3 = Severe; I avoided intercourse because of pain</li>
    <li style="margin-top:0.7ex;">Does not apply; I was not sexually active for reasons other than my endometriosis or did not have sexual intercourse</li>
  </ul>
  <p style="margin-top:0ex; margin-bottom:1ex;">The monthly mean 
dyspareunia score is the average of the daily values reported during the
 4 weeks prior to each visit. Responses of "does not apply" were not 
included in the calculations.</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and weeks 4 and 8 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 10 evaluable
 e-Diary reports during the double-blind period (intent-to-treat 
population) with non-missing data at each time point. If a participant's
 responses were all "does not apply" for that month the score was 
treated as missing.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo orally once a 
day for 8 weeks during the double-blind treatment period and switched to
 receive 150 mg elagolix for 16 weeks during the open-label treatment 
period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received 150 mg elagolix orally 
once a day for 8 weeks during the double-blind treatment period and 
continued to receive 150 mg elagolix for 16 additional weeks during the 
open-label treatment period.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;59&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;53&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline in the Monthly Mean 
Dyspareunia Score During the Double-Blind Treatment Phase&nbsp;         
               <br><span class="body3">[Units:&nbsp;Units&nbsp;on&nbsp;a&nbsp;scale]<br>Least Squares Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 4&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;54&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;49&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 4&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.07&nbsp;&nbsp;(0.087)&nbsp;
                                                                        
                              </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.34&nbsp;&nbsp;(0.091)&nbsp;
                                                                        
                              </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 8&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;51&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;48&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 8&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.23&nbsp;&nbsp;(0.095)&nbsp;
                                                                        
                              </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.61&nbsp;&nbsp;(0.098)&nbsp;
                                                                        
                              </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                                                <br>
                  <span class="header3">Statistical Analysis 1 for Change From Baseline in the Monthly Mean Dyspareunia Score During the Double-Blind Treatment Phase</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">All groups</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">ANCOVA</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0360</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.27</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.52 to -0.02</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.127)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Comparison of change form baseline at week 4
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          ANCOVA model including baseline value as a covariate.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 2 for Change From Baseline in the Monthly Mean Dyspareunia Score During the Double-Blind Treatment Phase</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">All groups</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">ANCOVA</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0070</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.38</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.65 to -0.11</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.137)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Comparison of change from baseline at week 8
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          ANCOVA model including baseline value as a covariate.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                            <br>
              <br>
                              </div>
              <a name="outcome8" id="outcome8"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">8.&nbsp; Primary: &nbsp; </td>
            <td>Change From Baseline in the Monthly Mean Dyspareunia 
Score During the Open-label and Posttreatment Phases &nbsp; [ Time 
Frame: Baseline and Weeks 12, 16, 20, 24, and 30 (6 weeks posttreatment)
 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Primary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From Baseline in the Monthly Mean Dyspareunia Score During the Open-label and Posttreatment Phases</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">Participants
 assessed their dyspareunia (pain during sexual intercourse) at 
approximately the same time every day in an e-Diary according to the 
following response options:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">0: Absent; No discomfort during sexual intercourse</li>
    <li style="margin-top:0.7ex;">1: Mild; I was able to tolerate the discomfort during sexual intercourse</li>
    <li style="margin-top:0.7ex;">2: Moderate; Intercourse was interrupted due to pain</li>
    <li style="margin-top:0.7ex;">3: Severe; I avoided intercourse because of pain</li>
    <li style="margin-top:0.7ex;">Does not apply; I was not sexually active for reasons other than my endometriosis or did not have sexual intercourse</li>
  </ul>
  <p style="margin-top:0ex; margin-bottom:1ex;">The monthly mean 
dyspareunia score is the average of the daily values reported during the
 4 weeks prior to each visit, except for week 30 which is based on 6 
weeks of data. Responses of "does not apply" were not included in the 
calculations.</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and Weeks 12, 16, 20, 24, and 30 (6 weeks posttreatment) &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          Randomized participants who 
received at least 1 dose of study drug and had at least 10 evaluable 
e-Diary reports during the double-blind period (intent-to-treat 
population) with data on or after Week 12 and non-missing data at each 
time point. If a participant's responses were all "does not apply" for 
that month the score was treated as missing.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo orally once a 
day for 8 weeks during the double-blind treatment period and switched to
 receive 150 mg elagolix for 16 weeks during the open-label treatment 
period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received 150 mg elagolix orally 
once a day for 8 weeks during the double-blind treatment period and 
continued to receive 150 mg elagolix for 16 additional weeks during the 
open-label treatment period.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;53&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;47&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline in the Monthly Mean 
Dyspareunia Score During the Open-label and Posttreatment Phases&nbsp;  
                      <br><span class="body3">[Units:&nbsp;Units&nbsp;on&nbsp;a&nbsp;scale]<br>Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 12&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;49&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;46&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 12&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.334&nbsp;&nbsp;(0.125)&nbsp;                                   
                                                                   </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.696&nbsp;&nbsp;(0.112)&nbsp;                                   
                                                                   </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 16&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;49&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 16&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.453&nbsp;&nbsp;(0.114)&nbsp;                                   
                                                                   </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.738&nbsp;&nbsp;(0.124)&nbsp;                                   
                                                                   </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 20&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 20&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.492&nbsp;&nbsp;(0.135)&nbsp;                                   
                                                                   </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.778&nbsp;&nbsp;(0.121)&nbsp;                                   
                                                                   </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 24&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;40&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;39&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 24&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.633&nbsp;&nbsp;(0.155)&nbsp;                                   
                                                                   </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.789&nbsp;&nbsp;(0.115)&nbsp;                                   
                                                                   </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 30&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;40&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 30&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.300&nbsp;&nbsp;(0.118)&nbsp;                                   
                                                                   </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.730&nbsp;&nbsp;(0.118)&nbsp;                                   
                                                                   </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                              <span class="header3">No statistical 
analysis provided for Change From Baseline in the Monthly Mean 
Dyspareunia Score During the Open-label and Posttreatment Phases</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome9" id="outcome9"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">9.&nbsp; Secondary: &nbsp; </td>
            <td>Percentage of Participants With a Response in Monthly 
Mean Dysmenorrhea Score at Week 8 &nbsp; [ Time Frame: Baseline and Week
 8 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Percentage of Participants With a Response in Monthly Mean Dysmenorrhea Score at Week 8</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">Participants
 assessed dysmenorrhea (pain during menstruation) and its impact on 
their daily activities at approximately the same time each day of their 
period in an e-Diary according to the following response options:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">0: No discomfort</li>
    <li style="margin-top:0.7ex;">1: Mild discomfort but I was easily able to do the things I usually do</li>
    <li style="margin-top:0.7ex;">2: Moderate discomfort or pain that made it difficult to do some of the things I usually do</li>
    <li style="margin-top:0.7ex;">3: Severe pain that made it difficult to do the things I usually do.</li>
  </ul>
  <p style="margin-top:0ex; margin-bottom:1ex;">The monthly mean dysmenorrhea score is the average of the daily values reported during the 4 weeks prior to each time point.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">Response was defined as 
the percentage of participants with a percent decrease from baseline in 
the week 8 monthly mean score that was greater than or equal to each 
specified threshold value (10% through 90% in steps of 10%).</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and Week 8 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 10 evaluable
 e-Diary reports during the double-blind period (intent-to-treat 
population) with non-missing data at baseline and week 8.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo orally once a 
day for 8 weeks during the double-blind treatment period and switched to
 receive 150 mg elagolix for 16 weeks during the open-label treatment 
period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received 150 mg elagolix orally 
once a day for 8 weeks during the double-blind treatment period and 
continued to receive 150 mg elagolix for 16 additional weeks during the 
open-label treatment period.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;64&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;64&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Percentage of Participants With a Response in 
Monthly Mean Dysmenorrhea Score at Week 8&nbsp;                        <br><span class="body3">[Units:&nbsp;Percentage&nbsp;of&nbsp;participants]<br></span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          10% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;56.3&nbsp;                                                        
  </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;68.8&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          20% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;43.8&nbsp;                                                        
  </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;68.8&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          30% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;32.8&nbsp;                                                        
  </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;62.5&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          40% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;25.0&nbsp;                                                        
  </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;59.4&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          50% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;15.6&nbsp;                                                        
  </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;54.7&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          60% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;9.4&nbsp;                                                         
 </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;51.6&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          70% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;4.7&nbsp;                                                         
 </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;46.9&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          80% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;3.1&nbsp;                                                         
 </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;43.8&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          90% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;3.1&nbsp;                                                         
 </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;43.8&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                                          </tbody></table>
            
                            <br>


                              <span class="header3">No statistical analysis provided for Percentage of Participants With a Response in Monthly Mean Dysmenorrhea Score at Week 8</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome10" id="outcome10"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">10.&nbsp; Secondary: &nbsp; </td>
            <td>Percentage of Participants With a Response in Monthly 
Mean Non-menstrual Pelvic Pain Score at Week 8 &nbsp; [ Time Frame: 
Baseline and Week 8 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Percentage of Participants With a Response in Monthly Mean Non-menstrual Pelvic Pain Score at Week 8</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">Participants
 assessed their pelvic pain not related to menses and its impact on 
their daily activities at approximately the same time each day they were
 not having their period in an e-Diary according to the following 
response options:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">0 = No discomfort</li>
    <li style="margin-top:0.7ex;">1 = Mild discomfort but I was easily able to do the things I usually do</li>
    <li style="margin-top:0.7ex;">2 = Moderate discomfort or pain that made it difficult to do some of the things I usually do</li>
    <li style="margin-top:0.7ex;">3 = Severe pain that made it difficult to do the things I usually do.</li>
  </ul>
  <p style="margin-top:0ex; margin-bottom:1ex;">The monthly mean 
non-menstrual pelvic pain score is the average of the daily values 
reported during the 4 weeks prior to each time point.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">Response is defined as 
the percentage of participants with a percent decrease from baseline in 
the week 8 monthly mean score that was greater than or equal to each 
specified threshold value (10% through 90% in steps of 10%).</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and Week 8 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 10 evaluable
 e-Diary reports during the double-blind period (intent-to-treat 
population) with non-missing data at baseline and week 8.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo orally once a 
day for 8 weeks during the double-blind treatment period and switched to
 receive 150 mg elagolix for 16 weeks during the open-label treatment 
period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received 150 mg elagolix orally 
once a day for 8 weeks during the double-blind treatment period and 
continued to receive 150 mg elagolix for 16 additional weeks during the 
open-label treatment period.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;64&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;64&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Percentage of Participants With a Response in 
Monthly Mean Non-menstrual Pelvic Pain Score at Week 8&nbsp;            
            <br><span class="body3">[Units:&nbsp;Percentage&nbsp;of&nbsp;participants]<br></span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          10% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;51.6&nbsp;                                                        
  </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;79.7&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          20% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;40.6&nbsp;                                                        
  </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;68.8&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          30% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;32.8&nbsp;                                                        
  </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;62.5&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          40% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;25.0&nbsp;                                                        
  </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;51.6&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          50% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;25.0&nbsp;                                                        
  </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;32.8&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          60% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;20.3&nbsp;                                                        
  </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;26.6&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          70% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;14.1&nbsp;                                                        
  </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;21.9&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          80% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;9.4&nbsp;                                                         
 </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;10.9&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          90% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;4.7&nbsp;                                                         
 </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;7.8&nbsp;                                                         
 </td>
                                                                        </tr>
                                                                                          </tbody></table>
            
                            <br>


                              <span class="header3">No statistical 
analysis provided for Percentage of Participants With a Response in 
Monthly Mean Non-menstrual Pelvic Pain Score at Week 8</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome11" id="outcome11"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">11.&nbsp; Secondary: &nbsp; </td>
            <td>Percentage of Participants With a Response in Monthly 
Mean Cumulative Pain Score at Week 8 &nbsp; [ Time Frame: Baseline and 
Week 8 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Percentage of Participants With a Response in Monthly Mean Cumulative Pain Score at Week 8</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">Participants
 assessed dysmenorrhea or non-menstrual pelvic pain at approximately the
 same time every day in an e-Diary according to the following:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">0 = No discomfort</li>
    <li style="margin-top:0.7ex;">1 = Mild discomfort</li>
    <li style="margin-top:0.7ex;">2 = Moderate discomfort or pain</li>
    <li style="margin-top:0.7ex;">3 = Severe pain</li>
  </ul>
  <p style="margin-top:0ex; margin-bottom:1ex;">The monthly mean 
cumulative pain score is the average of the daily values for all days 
(menstrual and non-menstrual) in the 4 weeks prior to each time point.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">Response is the 
percentage of participants with a percent decrease from baseline in the 
week 8 monthly mean score that was greater than or equal to each 
specified threshold value (10% through 90% in steps of 10%).</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and Week 8 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 10 evaluable
 e-Diary reports during the double-blind period (intent-to-treat 
population) with non-missing data at baseline and week 8.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo orally once a 
day for 8 weeks during the double-blind treatment period and switched to
 receive 150 mg elagolix for 16 weeks during the open-label treatment 
period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received 150 mg elagolix orally 
once a day for 8 weeks during the double-blind treatment period and 
continued to receive 150 mg elagolix for 16 additional weeks during the 
open-label treatment period.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;64&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;64&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Percentage of Participants With a Response in 
Monthly Mean Cumulative Pain Score at Week 8&nbsp;                      
  <br><span class="body3">[Units:&nbsp;Percentage&nbsp;of&nbsp;participants]<br></span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          10% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;51.6&nbsp;                                                        
  </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;76.6&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          20% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;40.6&nbsp;                                                        
  </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;70.3&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          30% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;37.5&nbsp;                                                        
  </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;59.4&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          40% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;23.4&nbsp;                                                        
  </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;46.9&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          50% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;20.3&nbsp;                                                        
  </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;37.5&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          60% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;15.6&nbsp;                                                        
  </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;26.6&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          70% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;7.8&nbsp;                                                         
 </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;18.8&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          80% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;3.1&nbsp;                                                         
 </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;9.4&nbsp;                                                         
 </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          90% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;0.0&nbsp;                                                         
 </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;9.4&nbsp;                                                         
 </td>
                                                                        </tr>
                                                                                          </tbody></table>
            
                            <br>


                              <span class="header3">No statistical analysis provided for Percentage of Participants With a Response in Monthly Mean Cumulative Pain Score at Week 8</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome12" id="outcome12"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">12.&nbsp; Secondary: &nbsp; </td>
            <td>Percentage of Participants With a Response in Monthly 
Mean Dyspareunia Score at Week 8 &nbsp; [ Time Frame: Baseline and Week 8
 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Percentage of Participants With a Response in Monthly Mean Dyspareunia Score at Week 8</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">Participants
 assessed their dyspareunia (pain during sexual intercourse) at 
approximately the same time every day in an e-Diary according to the 
following response options:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">0 = Absent; No discomfort during sexual intercourse</li>
    <li style="margin-top:0.7ex;">1 = Mild; I was able to tolerate the discomfort during sexual intercourse</li>
    <li style="margin-top:0.7ex;">2 = Moderate; Intercourse was interrupted due to pain</li>
    <li style="margin-top:0.7ex;">3 = Severe; I avoided intercourse because of pain</li>
    <li style="margin-top:0.7ex;">Does not apply; I was not sexually active for reasons other than my endometriosis or did not have sexual intercourse</li>
  </ul>
  <p style="margin-top:0ex; margin-bottom:1ex;">The monthly mean dyspareunia score is the average of the daily values reported during the 4 weeks prior to each time point.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">Response is defined as 
the percentage of participants with a percent decrease from baseline in 
the week 8 monthly mean score that was greater than or equal to each 
specified threshold value (10% through 90% in steps of 10%).</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and Week 8 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 10 evaluable
 e-Diary reports during the double-blind period (intent-to-treat 
population) with non-missing data at baseline and week 8. If a 
participant's responses were all "does not apply" for that month the 
score was treated as missing.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo orally once a 
day for 8 weeks during the double-blind treatment period and switched to
 receive 150 mg elagolix for 16 weeks during the open-label treatment 
period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received 150 mg elagolix orally 
once a day for 8 weeks during the double-blind treatment period and 
continued to receive 150 mg elagolix for 16 additional weeks during the 
open-label treatment period.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;47&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;45&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Percentage of Participants With a Response in 
Monthly Mean Dyspareunia Score at Week 8&nbsp;                        <br><span class="body3">[Units:&nbsp;Percentage&nbsp;of&nbsp;participants]<br></span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          10% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;44.7&nbsp;                                                        
  </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;73.3&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          20% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;38.3&nbsp;                                                        
  </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;64.4&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          30% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;34.0&nbsp;                                                        
  </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;57.8&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          40% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;27.7&nbsp;                                                        
  </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;53.3&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          50% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;23.4&nbsp;                                                        
  </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;48.9&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          60% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;19.1&nbsp;                                                        
  </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;37.8&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          70% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;19.1&nbsp;                                                        
  </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;31.1&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          80% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;17.0&nbsp;                                                        
  </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;22.2&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          90% Reduction&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;12.8&nbsp;                                                        
  </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                              
&nbsp;20.0&nbsp;                                                        
  </td>
                                                                        </tr>
                                                                                          </tbody></table>
            
                            <br>


                              <span class="header3">No statistical analysis provided for Percentage of Participants With a Response in Monthly Mean Dyspareunia Score at Week 8</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome13" id="outcome13"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">13.&nbsp; Secondary: &nbsp; </td>
            <td>Change From Baseline in the Percentage of Days of Any 
Analgesic Use During the Double-Blind Treatment Phase &nbsp; [ Time 
Frame: Baseline and Weeks 4 and 8 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From Baseline in the Percentage of Days of Any Analgesic Use During the Double-Blind Treatment Phase</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">The
 daily use of endometriosis analgesics was reported by participants 
daily using the e-Diary. Participants reported whether the medication 
was over-the-counter (OTC) or prescription, and, if prescription, 
whether the medication was a narcotic.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">The percentage of days 
of any analgesic use is defined as the number of days in the 4 weeks 
prior to each study visit that the participant reported the use of an 
analgesic, divided by the number of study days in the interval that the 
participant provided an e-Diary report regarding the use of 
endometriosis analgesics (including a response of “none”).</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and Weeks 4 and 8 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 10 evaluable
 e-Diary reports during the double-blind period (intent-to-treat 
population). The analysis includes participants with non-missing data at
 each time point.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo orally once a 
day for 8 weeks during the double-blind treatment period and switched to
 receive 150 mg elagolix for 16 weeks during the open-label treatment 
period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received 150 mg elagolix orally 
once a day for 8 weeks during the double-blind treatment period and 
continued to receive 150 mg elagolix for 16 additional weeks during the 
open-label treatment period.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;66&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;66&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline in the Percentage of Days 
of Any Analgesic Use During the Double-Blind Treatment Phase&nbsp;      
                  <br><span class="body3">[Units:&nbsp;Percentage&nbsp;of&nbsp;days]<br>Least Squares Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 4&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;66&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;66&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 4&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-5.78&nbsp;&nbsp;(2.782)&nbsp;
                                                                        
                              </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-15.62&nbsp;&nbsp;(2.782)&nbsp;                                   
                                                                   </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 8&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;64&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;64&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 8&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-9.19&nbsp;&nbsp;(2.763)&nbsp;
                                                                        
                              </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-21.63&nbsp;&nbsp;(2.763)&nbsp;                                   
                                                                   </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                                                <br>
                  <span class="header3">Statistical Analysis 1 for 
Change From Baseline in the Percentage of Days of Any Analgesic Use 
During the Double-Blind Treatment Phase</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">All groups</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">ANCOVA</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0137</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-9.84</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-17.63 to -2.05</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(3.939)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Comparison of change from baseline at week 4
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          ANCOVA model including baseline value as a covariate.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 2 for 
Change From Baseline in the Percentage of Days of Any Analgesic Use 
During the Double-Blind Treatment Phase</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">All groups</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">ANCOVA</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0019</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-12.44</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-20.19 to -4.70</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(3.913)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Comparison of change from baseline at week 8
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          ANCOVA model including baseline value as a covariate.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                            <br>
              <br>
                              </div>
              <a name="outcome14" id="outcome14"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">14.&nbsp; Secondary: &nbsp; </td>
            <td>Change From Baseline in the Percentage of Days of Any 
Analgesic Use During the Open-Label and Posttreatment Phases &nbsp; [ 
Time Frame: Baseline and Weeks 12, 16, 20, 24, and 30 (6 weeks 
posttreatment) ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From Baseline in the Percentage of Days of Any Analgesic Use During the Open-Label and Posttreatment Phases</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">The
 daily use of endometriosis analgesics was reported by participants 
daily using the e-Diary. Participants reported whether the medication 
was over-the-counter (OTC) or prescription, and, if prescription, 
whether the medication was a narcotic.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">The percentage of days 
of any analgesic use is defined as the number of days in the 4 weeks 
prior to each study visit (except for week 30 which is based on 6 weeks 
of data) that the participant reported the use of an analgesic, divided 
by the number of study days in the interval that the participant 
provided an e-Diary report regarding the use of endometriosis analgesics
 (including a response of "none").</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and Weeks 12, 16, 20, 24, and 30 (6 weeks posttreatment) &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 10 evaluable
 e-Diary reports during the double-blind period (intent-to-treat 
population) with data on or after Week 12. The analysis includes 
participants with non-missing data at each time point.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo orally once a 
day for 8 weeks during the double-blind treatment period and switched to
 receive 150 mg elagolix for 16 weeks during the open-label treatment 
period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received 150 mg elagolix orally 
once a day for 8 weeks during the double-blind treatment period and 
continued to receive 150 mg elagolix for 16 additional weeks during the 
open-label treatment period.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;61&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;60&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline in the Percentage of Days 
of Any Analgesic Use During the Open-Label and Posttreatment 
Phases&nbsp;                        <br><span class="body3">[Units:&nbsp;Percentage&nbsp;of&nbsp;days]<br>Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 12&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;61&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;60&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 12&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-14.91&nbsp;&nbsp;(3.76)&nbsp;
                                                                        
                              </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-27.70&nbsp;&nbsp;(3.49)&nbsp;
                                                                        
                              </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 16&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;61&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;59&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 16&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-18.34&nbsp;&nbsp;(3.33)&nbsp;
                                                                        
                              </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-26.27&nbsp;&nbsp;(3.71)&nbsp;
                                                                        
                              </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 20&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 20&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-19.82&nbsp;&nbsp;(4.05)&nbsp;
                                                                        
                              </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-26.35&nbsp;&nbsp;(4.27)&nbsp;
                                                                        
                              </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 24&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 24&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-20.63&nbsp;&nbsp;(4.17)&nbsp;
                                                                        
                              </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-29.21&nbsp;&nbsp;(4.23)&nbsp;
                                                                        
                              </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 30&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;55&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;55&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 30&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-11.64&nbsp;&nbsp;(4.18)&nbsp;
                                                                        
                              </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-21.83&nbsp;&nbsp;(4.30)&nbsp;
                                                                        
                              </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                              <span class="header3">No statistical 
analysis provided for Change From Baseline in the Percentage of Days of 
Any Analgesic Use During the Open-Label and Posttreatment Phases</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome15" id="outcome15"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">15.&nbsp; Secondary: &nbsp; </td>
            <td>Change From Baseline in the Percentage of Days of 
Prescription Analgesic Use During the Double-Blind Treatment Phase 
&nbsp; [ Time Frame: Baseline and Weeks 4 and 8 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From Baseline in the Percentage of Days of Prescription Analgesic Use During the Double-Blind Treatment Phase</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">The
 daily use of endometriosis analgesics was reported by participants 
daily using the e-Diary. Participants reported whether the medication 
was over-the-counter (OTC) or prescription, and, if prescription, 
whether the medication was a narcotic.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">The percentage of days 
of prescription analgesic use is defined as the number of days in the 4 
weeks prior to each study visit that the participant reported the use of
 a prescription analgesic, divided by the number of study days in the 
interval that the participant provided an e-Diary report regarding the 
use of endometriosis analgesics (including a response of “none”).</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and Weeks 4 and 8 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 10 evaluable
 e-Diary reports during the double-blind period (intent-to-treat 
population). The analysis includes participants with non-missing data at
 each time point.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo orally once a 
day for 8 weeks during the double-blind treatment period and switched to
 receive 150 mg elagolix for 16 weeks during the open-label treatment 
period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received 150 mg elagolix orally 
once a day for 8 weeks during the double-blind treatment period and 
continued to receive 150 mg elagolix for 16 additional weeks during the 
open-label treatment period.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;66&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;66&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline in the Percentage of Days 
of Prescription Analgesic Use During the Double-Blind Treatment 
Phase&nbsp;                        <br><span class="body3">[Units:&nbsp;Percentage&nbsp;of&nbsp;days]<br>Least Squares Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 4&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;66&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;66&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 4&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;0.92&nbsp;&nbsp;(1.929)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-5.29&nbsp;&nbsp;(1.929)&nbsp;
                                                                        
                              </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 8&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;64&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;64&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 8&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.82&nbsp;&nbsp;(1.802)&nbsp;
                                                                        
                              </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-7.16&nbsp;&nbsp;(1.802)&nbsp;
                                                                        
                              </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                                                <br>
                  <span class="header3">Statistical Analysis 1 for 
Change From Baseline in the Percentage of Days of Prescription Analgesic
 Use During the Double-Blind Treatment Phase</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">All groups</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">ANCOVA</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0244</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-6.21</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-11.61 to -0.81</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(2.728)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Comparison of change from baseline at week 4
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          ANCOVA model including baseline value as a covariate.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 2 for 
Change From Baseline in the Percentage of Days of Prescription Analgesic
 Use During the Double-Blind Treatment Phase</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">All groups</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">ANCOVA</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0141</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-6.35</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-11.39 to -1.30</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(2.549)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Comparison of change from baseline at week 8
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          ANCOVA model including baseline value as a covariate.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                            <br>
              <br>
                              </div>
              <a name="outcome16" id="outcome16"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">16.&nbsp; Secondary: &nbsp; </td>
            <td>Change From Baseline in the Percentage of Days of 
Prescription Analgesic Use During the Open-Label and Posttreatment 
Phases &nbsp; [ Time Frame: Baseline and Weeks 12, 16, 20, 24, and 30 (6
 weeks posttreatment) ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From Baseline in the Percentage of Days of Prescription Analgesic Use During the Open-Label and Posttreatment Phases</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">The
 daily use of endometriosis analgesics was reported by participants 
daily using the e-Diary. Participants reported whether the medication 
was over-the-counter (OTC) or prescription, and, if prescription, 
whether the medication was a narcotic.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">The percentage of days 
of prescription analgesic use is defined as the number of days in the 4 
weeks prior to each study visit (except for week 30 which is based on 6 
weeks of data) that the participant reported the use of a prescription 
analgesic, divided by the number of study days in the interval that the 
participant provided an e-Diary report regarding the use of 
endometriosis analgesics (including a response of "none").</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and Weeks 12, 16, 20, 24, and 30 (6 weeks posttreatment) &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 10 evaluable
 e-Diary reports during the double-blind period (intent-to-treat 
population) with data on or after Week 12. The analysis includes 
participants with non-missing data at each time point.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo orally once a 
day for 8 weeks during the double-blind treatment period and switched to
 receive 150 mg elagolix for 16 weeks during the open-label treatment 
period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received 150 mg elagolix orally 
once a day for 8 weeks during the double-blind treatment period and 
continued to receive 150 mg elagolix for 16 additional weeks during the 
open-label treatment period.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;61&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;60&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline in the Percentage of Days 
of Prescription Analgesic Use During the Open-Label and Posttreatment 
Phases&nbsp;                        <br><span class="body3">[Units:&nbsp;Percentage&nbsp;of&nbsp;days]<br>Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 12&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;61&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;60&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 12&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-2.34&nbsp;&nbsp;(2.70)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-8.53&nbsp;&nbsp;(1.66)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 16&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;61&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;59&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 16&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-5.52&nbsp;&nbsp;(2.26)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-7.52&nbsp;&nbsp;(1.67)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 20&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 20&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-5.21&nbsp;&nbsp;(2.78)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-6.06&nbsp;&nbsp;(2.31)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 24&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 24&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-5.89&nbsp;&nbsp;(2.56)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-7.83&nbsp;&nbsp;(1.89)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 30&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;55&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;55&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 30&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.72&nbsp;&nbsp;(3.07)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-6.06&nbsp;&nbsp;(2.26)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                              <span class="header3">No statistical 
analysis provided for Change From Baseline in the Percentage of Days of 
Prescription Analgesic Use During the Open-Label and Posttreatment 
Phases</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome17" id="outcome17"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">17.&nbsp; Secondary: &nbsp; </td>
            <td>Change From Baseline in the Percentage of Days of 
Narcotic Analgesic Use During the Double-Blind Treatment Phase &nbsp; [ 
Time Frame: Baseline and Weeks 4 and 8 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From Baseline in the Percentage of Days of Narcotic Analgesic Use During the Double-Blind Treatment Phase</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">The
 daily use of endometriosis analgesics was reported by participants 
daily using the e-Diary. Participants reported whether the medication 
was over-the-counter (OTC) or prescription, and, if prescription, 
whether the medication was a narcotic.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">The percentage of days 
of narcotic analgesic use is defined as the number of days in the 4 
weeks prior to each study visit that the participant reported the use of
 a narcotic analgesic, divided by the number of study days in the 
interval that the participant provided an e-Diary report regarding the 
use of endometriosis analgesics (including a response of “none”).</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and Weeks 4 and 8 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 10 evaluable
 e-Diary reports during the double-blind period (intent-to-treat 
population). The analysis includes participants with non-missing data at
 each time point.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo orally once a 
day for 8 weeks during the double-blind treatment period and switched to
 receive 150 mg elagolix for 16 weeks during the open-label treatment 
period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received 150 mg elagolix orally 
once a day for 8 weeks during the double-blind treatment period and 
continued to receive 150 mg elagolix for 16 additional weeks during the 
open-label treatment period.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;66&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;66&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline in the Percentage of Days 
of Narcotic Analgesic Use During the Double-Blind Treatment Phase&nbsp; 
                       <br><span class="body3">[Units:&nbsp;Percentage&nbsp;of&nbsp;days]<br>Least Squares Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 4&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;66&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;66&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 4&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.51&nbsp;&nbsp;(1.287)&nbsp;
                                                                        
                              </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-3.63&nbsp;&nbsp;(1.287)&nbsp;
                                                                        
                              </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 8&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;64&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;64&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 8&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-1.19&nbsp;&nbsp;(1.369)&nbsp;
                                                                        
                              </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-4.71&nbsp;&nbsp;(1.369)&nbsp;
                                                                        
                              </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                                                <br>
                  <span class="header3">Statistical Analysis 1 for 
Change From Baseline in the Percentage of Days of Narcotic Analgesic Use
 During the Double-Blind Treatment Phase</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">All groups</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">ANCOVA</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0893</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-3.12</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-6.72 to 0.49</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(1.821)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Comparison of change from baseline at week 4
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          ANCOVA model including baseline value as a covariate.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 2 for 
Change From Baseline in the Percentage of Days of Narcotic Analgesic Use
 During the Double-Blind Treatment Phase</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">All groups</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">ANCOVA</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0720</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-3.52</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-7.35 to 0.32</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(1.938)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Comparison of change from baseline at week 8
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          ANCOVA model including baseline value as a covariate.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                            <br>
              <br>
                              </div>
              <a name="outcome18" id="outcome18"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">18.&nbsp; Secondary: &nbsp; </td>
            <td>Change From Baseline in the Percentage of Days of 
Narcotic Analgesic Use During the Open-Label and Posttreatment Phases 
&nbsp; [ Time Frame: Baseline and Weeks 12, 16, 20, 24, and 30 (6 weeks 
posttreatment) ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From Baseline in the Percentage of Days of Narcotic Analgesic Use During the Open-Label and Posttreatment Phases</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">The
 daily use of endometriosis analgesics was reported by participants 
daily using the e-Diary. Participants reported whether the medication 
was over-the-counter (OTC) or prescription, and, if prescription, 
whether the medication was a narcotic.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">The percentage of days 
of narcotic analgesic use is defined as the number of days in the 4 
weeks prior to each study visit (except for week 30 which is based on 6 
weeks of data) that the participant reported the use of a narcotic 
analgesic, divided by the number of study days in the interval that the 
participant provided an e-Diary report regarding the use of 
endometriosis analgesics (including a response of "none").</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and Weeks 12, 16, 20, 24, and 30 (6 weeks posttreatment) &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 10 evaluable
 e-Diary reports during the double-blind period (intent-to-treat 
population) with data on or after Week 12. The analysis includes 
participants with non-missing data at each time point.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo orally once a 
day for 8 weeks during the double-blind treatment period and switched to
 receive 150 mg elagolix for 16 weeks during the open-label treatment 
period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received 150 mg elagolix orally 
once a day for 8 weeks during the double-blind treatment period and 
continued to receive 150 mg elagolix for 16 additional weeks during the 
open-label treatment period.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;61&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;60&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline in the Percentage of Days 
of Narcotic Analgesic Use During the Open-Label and Posttreatment 
Phases&nbsp;                        <br><span class="body3">[Units:&nbsp;Percentage&nbsp;of&nbsp;days]<br>Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 12&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;61&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;60&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 12&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-1.91&nbsp;&nbsp;(2.16)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-4.79&nbsp;&nbsp;(1.25)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 16&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;61&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;59&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 16&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-4.03&nbsp;&nbsp;(1.76)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-3.64&nbsp;&nbsp;(1.27)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 20&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 20&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-2.79&nbsp;&nbsp;(2.24)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-5.41&nbsp;&nbsp;(1.64)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 24&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 24&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-3.12&nbsp;&nbsp;(2.20)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-3.92&nbsp;&nbsp;(1.68)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 30&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;55&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;55&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 30&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;0.75&nbsp;&nbsp;(2.73)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-3.56&nbsp;&nbsp;(1.69)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                              <span class="header3">No statistical 
analysis provided for Change From Baseline in the Percentage of Days of 
Narcotic Analgesic Use During the Open-Label and Posttreatment Phases</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome19" id="outcome19"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">19.&nbsp; Secondary: &nbsp; </td>
            <td>Change From Baseline to the End of the Double-blind 
Treatment Phase in Composite Pelvic Signs and Symptoms Score (CPSSS) 
Total Score and Component Scores &nbsp; [ Time Frame: Baseline and Week 8
 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From 
Baseline to the End of the Double-blind Treatment Phase in Composite 
Pelvic Signs and Symptoms Score (CPSSS) Total Score and Component Scores</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">The
 CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, 
non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. 
Each component was scored on a scale of 0 to 3 (0 = absent, 1 = mild, 2 =
 moderate, and 3 = severe).</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">Dysmenorrhea, 
dyspareunia, and non-menstrual pelvic pain scores are based on the 
participant's assessment of symptoms during the past 28 days; pelvic 
tenderness and induration were assessed by the investigator based on 
findings associated with a pelvic examination.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">The total CPSSS has a 
maximum possible value of 15 (total score range: 0 to 15, where a lower 
score indicates less signs and symptoms of endometriosis or better 
functioning). Individual component scores range from 0 (absent) to 3 
(severe).</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and Week 8 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 10 evaluable
 e-Diary reports during the double-blind period (intent-to-treat 
population). The analysis includes participants with non-missing data at
 baseline and week 8.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo orally once a 
day for 8 weeks during the double-blind treatment period and switched to
 receive 150 mg elagolix for 16 weeks during the open-label treatment 
period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received 150 mg elagolix orally 
once a day for 8 weeks during the double-blind treatment period and 
continued to receive 150 mg elagolix for 16 additional weeks during the 
open-label treatment period.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;66&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;66&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline to the End of the 
Double-blind Treatment Phase in Composite Pelvic Signs and Symptoms 
Score (CPSSS) Total Score and Component Scores&nbsp;                    
    <br><span class="body3">[Units:&nbsp;Units&nbsp;on&nbsp;a&nbsp;scale]<br>Least Squares Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Total Score&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;62&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;63&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Total Score&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-2.19&nbsp;&nbsp;(0.359)&nbsp;
                                                                        
                              </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-4.45&nbsp;&nbsp;(0.356)&nbsp;
                                                                        
                              </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Dysmenorrhea Component&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;63&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;63&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Dysmenorrhea Component&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.39&nbsp;&nbsp;(0.127)&nbsp;
                                                                        
                              </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-1.44&nbsp;&nbsp;(0.127)&nbsp;
                                                                        
                              </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Non-menstrual Pelvic Pain Component&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;63&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;63&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Non-menstrual Pelvic Pain Component&nbsp; 
                                                         </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.54&nbsp;&nbsp;(0.101)&nbsp;
                                                                        
                              </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.90&nbsp;&nbsp;(0.101)&nbsp;
                                                                        
                              </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Dyspareunia Component&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;50&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;51&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Dyspareunia Component&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.46&nbsp;&nbsp;(0.123)&nbsp;
                                                                        
                              </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.74&nbsp;&nbsp;(0.121)&nbsp;
                                                                        
                              </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Pelvic Tenderness Component&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;62&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;63&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Pelvic Tenderness Component&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.41&nbsp;&nbsp;(0.102)&nbsp;
                                                                        
                              </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.80&nbsp;&nbsp;(0.101)&nbsp;
                                                                        
                              </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Pelvic Induration Component&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;62&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;63&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Pelvic Induration Component&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.38&nbsp;&nbsp;(0.089)&nbsp;
                                                                        
                              </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.66&nbsp;&nbsp;(0.088)&nbsp;
                                                                        
                              </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                                                <br>
                  <span class="header3">Statistical Analysis 1 for 
Change From Baseline to the End of the Double-blind Treatment Phase in 
Composite Pelvic Signs and Symptoms Score (CPSSS) Total Score and 
Component Scores</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">All groups</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">ANCOVA</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">&lt; 0.0001</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-2.26</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-3.26 to -1.26</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.505)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Comparison of the change from baseline in CPSSS total score
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          ANCOVA model including baseline value as a covariate.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 2 for 
Change From Baseline to the End of the Double-blind Treatment Phase in 
Composite Pelvic Signs and Symptoms Score (CPSSS) Total Score and 
Component Scores</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">All groups</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">ANCOVA</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">&lt; 0.0001</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-1.05</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-1.41 to -0.69</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.180)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Comparison of 
change from baseline in CPSSS component of dysmenorrhea score
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          ANCOVA model including baseline value as a covariate.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 3 for 
Change From Baseline to the End of the Double-blind Treatment Phase in 
Composite Pelvic Signs and Symptoms Score (CPSSS) Total Score and 
Component Scores</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">All groups</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">ANCOVA</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0139</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.36</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.64 to -0.07</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.143)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Comparison of 
change from baseline in CPSSS component of non-menstrual pelvic pain 
score
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          ANCOVA model including baseline value as a covariate.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 4 for 
Change From Baseline to the End of the Double-blind Treatment Phase in 
Composite Pelvic Signs and Symptoms Score (CPSSS) Total Score and 
Component Scores</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">All groups</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">ANCOVA</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.1052</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.28</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.63 to 0.06</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.173)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Comparison of change from baseline in CPSSS component of dyspareunia score
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          ANCOVA model including baseline value as a covariate.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 5 for 
Change From Baseline to the End of the Double-blind Treatment Phase in 
Composite Pelvic Signs and Symptoms Score (CPSSS) Total Score and 
Component Scores</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">All groups</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">ANCOVA</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0081</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.39</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.67 to -0.10</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.143)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Comparison of 
change from baseline in CPSSS component of pelvic tenderness score
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          ANCOVA model including baseline value as a covariate.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 6 for 
Change From Baseline to the End of the Double-blind Treatment Phase in 
Composite Pelvic Signs and Symptoms Score (CPSSS) Total Score and 
Component Scores</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">All groups</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">ANCOVA</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0240</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.29</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.53 to -0.04</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.125)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Comparison of change from baseline in CPSSS component of induration score
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          ANCOVA model including baseline value as a covariate.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                            <br>
              <br>
                              </div>
              <a name="outcome20" id="outcome20"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">20.&nbsp; Secondary: &nbsp; </td>
            <td>Change From Baseline to the End of the Open-label 
Treatment Phase in Composite Pelvic Signs and Symptoms Score (CPSSS) 
Total Score and Component Scores &nbsp; [ Time Frame: Baseline and week 
24 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From 
Baseline to the End of the Open-label Treatment Phase in Composite 
Pelvic Signs and Symptoms Score (CPSSS) Total Score and Component Scores</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">The
 CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, 
non-menstrual pelvic pain, pelvic tenderness, and pelvic induration. 
Each component was scored on a scale of 0 to 3 (0 = absent, 1 = mild, 2 =
 moderate, and 3 = severe).</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">Dysmenorrhea, 
dyspareunia, and non-menstrual pelvic pain scores are based on the 
participant's assessment of symptoms during the past 28 days; pelvic 
tenderness and induration were assessed by the investigator based on 
findings associated with a pelvic examination.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">The total CPSSS has a 
maximum possible value of 15 (total score range: 0 to 15, where a lower 
score indicates less signs and symptoms of endometriosis or better 
functioning). Individual component scores range from 0 (absent) to 3 
(severe).</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and week 24 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 10 evaluable
 e-Diary reports during the double-blind period (intent-to-treat 
population) with data on or after Week 24. The analysis includes 
participants with non-missing data for each component at baseline and 
week 24.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo orally once a 
day for 8 weeks during the double-blind treatment period and switched to
 receive 150 mg elagolix for 16 weeks during the open-label treatment 
period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received 150 mg elagolix orally 
once a day for 8 weeks during the double-blind treatment period and 
continued to receive 150 mg elagolix for 16 additional weeks during the 
open-label treatment period.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;57&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;57&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline to the End of the 
Open-label Treatment Phase in Composite Pelvic Signs and Symptoms Score 
(CPSSS) Total Score and Component Scores&nbsp;                        <br><span class="body3">[Units:&nbsp;Units&nbsp;on&nbsp;a&nbsp;scale]<br>Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Total Score&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;56&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Total Score&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-5.571&nbsp;&nbsp;(0.451)&nbsp;                                   
                                                                   </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-5.404&nbsp;&nbsp;(0.384)&nbsp;                                   
                                                                   </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Dysmenorrhea Component&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Dysmenorrhea Component&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-1.544&nbsp;&nbsp;(0.175)&nbsp;                                   
                                                                   </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-1.386&nbsp;&nbsp;(0.175)&nbsp;                                   
                                                                   </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Non-menstrual Pelvic Pain Component&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Non-menstrual Pelvic Pain Component&nbsp; 
                                                         </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-1.000&nbsp;&nbsp;(0.128)&nbsp;                                   
                                                                   </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-1.211&nbsp;&nbsp;(0.127)&nbsp;                                   
                                                                   </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Dyspareunia Component&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Dyspareunia Component&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-1.12&nbsp;&nbsp;(0.17)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.77&nbsp;&nbsp;(0.16)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Pelvic Tenderness Component&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;56&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Pelvic Tenderness Component&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-1.000&nbsp;&nbsp;(0.120)&nbsp;                                   
                                                                   </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-1.175&nbsp;&nbsp;(0.112)&nbsp;                                   
                                                                   </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Pelvic Induration Component&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;56&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Pelvic Induration Component&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.964&nbsp;&nbsp;(0.142)&nbsp;                                   
                                                                   </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    
&nbsp;-0.807&nbsp;&nbsp;(0.121)&nbsp;                                   
                                                                   </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                              <span class="header3">No statistical 
analysis provided for Change From Baseline to the End of the Open-label 
Treatment Phase in Composite Pelvic Signs and Symptoms Score (CPSSS) 
Total Score and Component Scores</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome21" id="outcome21"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">21.&nbsp; Secondary: &nbsp; </td>
            <td>Patient Global Impression of Change During the Double-blind Treatment Phase &nbsp; [ Time Frame: Weeks 4 and 8 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Patient Global Impression of Change During the Double-blind Treatment Phase</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">The
 Patient Global Impression of Change (PGIC) is a questionnaire-based 
assessment of the change in endometriosis pain since the initiation of 
study drug. The participant was asked to select from one of seven 
response categories:</p>
  <ol style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Very Much Improved</li>
    <li style="margin-top:0.7ex;">Much Improved</li>
    <li style="margin-top:0.7ex;">Minimally Improved</li>
    <li style="margin-top:0.7ex;">Not Changed</li>
    <li style="margin-top:0.7ex;">Minimally Worse</li>
    <li style="margin-top:0.7ex;">Much Worse</li>
    <li style="margin-top:0.7ex;">Very Much Worse</li>
  </ol>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Weeks 4 and 8 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 10 evaluable
 e-Diary reports during the double-blind period (intent-to-treat 
population). The analysis includes participants with non-missing data at
 each time point.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo orally once a 
day for 8 weeks during the double-blind treatment period and switched to
 receive 150 mg elagolix for 16 weeks during the open-label treatment 
period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received 150 mg elagolix orally 
once a day for 8 weeks during the double-blind treatment period and 
continued to receive 150 mg elagolix for 16 additional weeks during the 
open-label treatment period.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;66&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;66&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Patient Global Impression of Change During the 
Double-blind Treatment Phase&nbsp;                        <br><span class="body3">[Units:&nbsp;Units&nbsp;on&nbsp;a&nbsp;scale]<br>Least Squares Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 4&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;65&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;66&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 4&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;3.6&nbsp;&nbsp;(0.16)&nbsp;   
                                                                        
                           </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;2.8&nbsp;&nbsp;(0.16)&nbsp;   
                                                                        
                           </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 8&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;63&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;63&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 8&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;3.4&nbsp;&nbsp;(0.18)&nbsp;   
                                                                        
                           </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;2.4&nbsp;&nbsp;(0.18)&nbsp;   
                                                                        
                           </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                                                <br>
                  <span class="header3">Statistical Analysis 1 for Patient Global Impression of Change During the Double-blind Treatment Phase</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">All groups</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">ANOVA</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0012</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.8</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-1.2 to -0.3</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.23)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Comparison of Patient Global Impression of Change at week 4
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 2 for Patient Global Impression of Change During the Double-blind Treatment Phase</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">All groups</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">ANOVA</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0002</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-1.0</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-1.5 to -0.5</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.26)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Comparison of Patient Global Impression of Change at week 8
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                            <br>
              <br>
                              </div>
              <a name="outcome22" id="outcome22"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">22.&nbsp; Secondary: &nbsp; </td>
            <td>Patient Global Impression of Change During the 
Open-Label and Posttreatment Phases &nbsp; [ Time Frame: Weeks 12, 16, 
20, 24, and 30 (6 weeks posttreatment) ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Patient Global Impression of Change During the Open-Label and Posttreatment Phases</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">The
 Patient Global Impression of Change (PGIC) is a questionnaire-based 
assessment of the change in endometriosis pain since the initiation of 
study drug. The participant was asked to select from one of seven 
response categories:</p>
  <ol style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Very Much Improved</li>
    <li style="margin-top:0.7ex;">Much Improved</li>
    <li style="margin-top:0.7ex;">Minimally Improved</li>
    <li style="margin-top:0.7ex;">Not Changed</li>
    <li style="margin-top:0.7ex;">Minimally Worse</li>
    <li style="margin-top:0.7ex;">Much Worse</li>
    <li style="margin-top:0.7ex;">Very Much Worse</li>
  </ol>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Weeks 12, 16, 20, 24, and 30 (6 weeks posttreatment) &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 10 evaluable
 e-Diary reports during the double-blind period (intent-to-treat 
population) with data on or after Week 12. The analysis includes 
participants with non-missing data at each time point.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo orally once a 
day for 8 weeks during the double-blind treatment period and switched to
 receive 150 mg elagolix for 16 weeks during the open-label treatment 
period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received 150 mg elagolix orally 
once a day for 8 weeks during the double-blind treatment period and 
continued to receive 150 mg elagolix for 16 additional weeks during the 
open-label treatment period.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;61&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;60&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Patient Global Impression of Change During the 
Open-Label and Posttreatment Phases&nbsp;                        <br><span class="body3">[Units:&nbsp;Units&nbsp;on&nbsp;a&nbsp;scale]<br>Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 12&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;61&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;59&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 12&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;2.5&nbsp;&nbsp;(0.2)&nbsp;    
                                                                        
                          </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;2.0&nbsp;&nbsp;(0.1)&nbsp;    
                                                                        
                          </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 16&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;60&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;59&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 16&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;2.4&nbsp;&nbsp;(0.2)&nbsp;    
                                                                        
                          </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;1.8&nbsp;&nbsp;(0.1)&nbsp;    
                                                                        
                          </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 20&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 20&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;2.2&nbsp;&nbsp;(0.2)&nbsp;    
                                                                        
                          </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;2.0&nbsp;&nbsp;(0.1)&nbsp;    
                                                                        
                          </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 24&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 24&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;2.0&nbsp;&nbsp;(0.2)&nbsp;    
                                                                        
                          </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;1.8&nbsp;&nbsp;(0.1)&nbsp;    
                                                                        
                          </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 30&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;55&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;53&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 30&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;2.4&nbsp;&nbsp;(0.2)&nbsp;    
                                                                        
                          </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;2.2&nbsp;&nbsp;(0.2)&nbsp;    
                                                                        
                          </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                              <span class="header3">No statistical analysis provided for Patient Global Impression of Change During the Open-Label and Posttreatment Phases</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome23" id="outcome23"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">23.&nbsp; Secondary: &nbsp; </td>
            <td>Percentage of Participants With a PGIC Response of Much 
Improved or Very Much Improved During the Double-blind Treatment Phase 
&nbsp; [ Time Frame: Weeks 4 and 8 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Percentage of Participants With a PGIC Response of Much Improved or Very Much Improved During the Double-blind Treatment Phase</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">The
 Patient Global Impression of Change (PGIC) is a questionnaire-based 
assessment of the change in endometriosis pain since the initiation of 
study drug. The participant was asked to select from one of seven 
response categories:</p>
  <ol style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Very Much Improved</li>
    <li style="margin-top:0.7ex;">Much Improved</li>
    <li style="margin-top:0.7ex;">Minimally Improved</li>
    <li style="margin-top:0.7ex;">Not Changed</li>
    <li style="margin-top:0.7ex;">Minimally Worse</li>
    <li style="margin-top:0.7ex;">Much Worse</li>
    <li style="margin-top:0.7ex;">Very Much Worse</li>
  </ol>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Weeks 4 and 8 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 10 evaluable
 e-Diary reports during the double-blind period (intent-to-treat 
population). The analysis includes participants with non-missing data at
 each time point.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo orally once a 
day for 8 weeks during the double-blind treatment period and switched to
 receive 150 mg elagolix for 16 weeks during the open-label treatment 
period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received 150 mg elagolix orally 
once a day for 8 weeks during the double-blind treatment period and 
continued to receive 150 mg elagolix for 16 additional weeks during the 
open-label treatment period.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;66&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;66&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Percentage of Participants With a PGIC Response 
of Much Improved or Very Much Improved During the Double-blind Treatment
 Phase&nbsp;                        <br><span class="body3">[Units:&nbsp;Percentage&nbsp;of&nbsp;participants]<br>Number (95% Confidence Interval)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 4&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;65&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;66&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 4&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;18.5&nbsp;<br>
                                      &nbsp;(9.0&nbsp;to&nbsp;27.9)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;37.9&nbsp;<br>
                                      &nbsp;(26.2&nbsp;to&nbsp;49.6)&nbsp;
                                                                                                      </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 8&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;63&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;63&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 8&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;30.2&nbsp;<br>
                                      &nbsp;(18.8&nbsp;to&nbsp;41.5)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;60.3&nbsp;<br>
                                      &nbsp;(48.2&nbsp;to&nbsp;72.4)&nbsp;
                                                                                                      </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                                                <br>
                  <span class="header3">Statistical Analysis 1 for 
Percentage of Participants With a PGIC Response of Much Improved or Very
 Much Improved During the Double-blind Treatment Phase</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">All groups</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Pearson chi-squared</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0136</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">19.4</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">4.4 to 34.4</td>
                            </tr>
                                                                                                                      
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Comparison of response rates at week 4
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 2 for 
Percentage of Participants With a PGIC Response of Much Improved or Very
 Much Improved During the Double-blind Treatment Phase</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">All groups</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Pearson chi-squared</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0007</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">30.2</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">13.6 to 46.7</td>
                            </tr>
                                                                                                                      
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Comparison of response rates at week 8
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                            <br>
              <br>
                              </div>
              <a name="outcome24" id="outcome24"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">24.&nbsp; Secondary: &nbsp; </td>
            <td>Percentage of Participants With a PGIC Response of Much 
Improved or Very Much Improved During the Open-label Treatment Phase 
&nbsp; [ Time Frame: Weeks 12, 16, 20, 24, and 30 (6 weeks 
posttreatment) ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Percentage of Participants With a PGIC Response of Much Improved or Very Much Improved During the Open-label Treatment Phase</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">The
 Patient Global Impression of Change (PGIC) is a questionnaire-based 
assessment of the change in endometriosis pain since the initiation of 
study drug. The participant was asked to select from one of seven 
response categories:</p>
  <ol style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Very Much Improved</li>
    <li style="margin-top:0.7ex;">Much Improved</li>
    <li style="margin-top:0.7ex;">Minimally Improved</li>
    <li style="margin-top:0.7ex;">Not Changed</li>
    <li style="margin-top:0.7ex;">Minimally Worse</li>
    <li style="margin-top:0.7ex;">Much Worse</li>
    <li style="margin-top:0.7ex;">Very Much Worse</li>
  </ol>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Weeks 12, 16, 20, 24, and 30 (6 weeks posttreatment) &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 10 evaluable
 e-Diary reports during the double-blind period (intent-to-treat 
population) with data on or after Week 12. The analysis includes 
participants with non-missing data at each time point.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo orally once a 
day for 8 weeks during the double-blind treatment period and switched to
 receive 150 mg elagolix for 16 weeks during the open-label treatment 
period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received 150 mg elagolix orally 
once a day for 8 weeks during the double-blind treatment period and 
continued to receive 150 mg elagolix for 16 additional weeks during the 
open-label treatment period.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;61&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;60&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Percentage of Participants With a PGIC Response 
of Much Improved or Very Much Improved During the Open-label Treatment 
Phase&nbsp;                        <br><span class="body3">[Units:&nbsp;Percentage&nbsp;of&nbsp;participants]<br></span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 12&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;61&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;59&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 12&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;59.0&nbsp;                                                        
          </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;76.3&nbsp;                                                        
          </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 16&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;60&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;59&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 16&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;61.7&nbsp;                                                        
          </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;76.3&nbsp;                                                        
          </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 20&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 20&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;71.9&nbsp;                                                        
          </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;71.9&nbsp;                                                        
          </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 24&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 24&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;73.7&nbsp;                                                        
          </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;86.0&nbsp;                                                        
          </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 30&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;55&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;53&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 30&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;69.1&nbsp;                                                        
          </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;73.6&nbsp;                                                        
          </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                              <span class="header3">No statistical 
analysis provided for Percentage of Participants With a PGIC Response of
 Much Improved or Very Much Improved During the Open-label Treatment 
Phase</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome25" id="outcome25"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">25.&nbsp; Secondary: &nbsp; </td>
            <td>Change From Baseline to the End of the Double-blind 
Treatment Phase in Endometriosis Health Profile-5 (EHP-5) &nbsp; [ Time 
Frame: Baseline and week 8 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From Baseline to the End of the Double-blind Treatment Phase in Endometriosis Health Profile-5 (EHP-5)</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">The
 EHP-5 is an instrument to measure health-related quality of life in 
women with endometriosis. The EHP-5 consists of two parts:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">A core questionnaire consisting of 
five questions that measure the impact of endometriosis in areas of 
pain, control and powerlessness, emotional well-being, social support, 
and self-image with five response categories for each item (Never, 
Rarely, Sometimes, Often, Always)</li>
    <li style="margin-top:0.7ex;">A supplemental questionnaire 
consisting of six additional questions which assess the impact of 
endometriosis on the areas of work, relationship with children, sexual 
intercourse, feelings about the medical profession, treatment, and 
infertility with the same five response categories plus an additional 
response category of Not Relevant which was not scored.</li>
  </ul>
  <p style="margin-top:0ex; margin-bottom:1ex;">The scores associated 
with each possible outcome category are as follows: never (0), rarely 
(25), sometimes (50), often (75), and always (100). A negative change 
from baseline score indicates improvement in quality of life.</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and week 8 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 10 evaluable
 e-Diary reports during the double-blind period (intent-to-treat 
population). The analysis includes participants with non-missing data at
 baseline and week 8 for each question.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo orally once a 
day for 8 weeks during the double-blind treatment period and switched to
 receive 150 mg elagolix for 16 weeks during the open-label treatment 
period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received 150 mg elagolix orally 
once a day for 8 weeks during the double-blind treatment period and 
continued to receive 150 mg elagolix for 16 additional weeks during the 
open-label treatment period.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;63&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;63&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline to the End of the 
Double-blind Treatment Phase in Endometriosis Health Profile-5 
(EHP-5)&nbsp;                        <br><span class="body3">[Units:&nbsp;Units&nbsp;on&nbsp;a&nbsp;scale]<br>Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Pain&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;63&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;63&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Pain&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-12.3&nbsp;&nbsp;(3.2)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-29.0&nbsp;&nbsp;(3.0)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Control and Powerlessness&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;63&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;63&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Control and Powerlessness&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-12.7&nbsp;&nbsp;(3.2)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-35.3&nbsp;&nbsp;(3.7)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Emotional Well-being&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;63&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;63&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Emotional Well-being&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-10.3&nbsp;&nbsp;(2.9)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-17.1&nbsp;&nbsp;(3.1)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Social Support&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;63&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;63&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Social Support&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-13.1&nbsp;&nbsp;(3.5)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-27.8&nbsp;&nbsp;(3.9)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Self-image&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;63&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;63&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Self-image&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-7.1&nbsp;&nbsp;(3.3)&nbsp;   
                                                                        
                           </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-23.4&nbsp;&nbsp;(3.5)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Work&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;54&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;54&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Work&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-13.0&nbsp;&nbsp;(3.4)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-26.4&nbsp;&nbsp;(3.4)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Relationship with Children&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;25&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;23&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Relationship with Children&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-19.0&nbsp;&nbsp;(4.8)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-31.5&nbsp;&nbsp;(5.5)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Sexual Intercourse&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;56&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;52&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Sexual Intercourse&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-14.3&nbsp;&nbsp;(2.9)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-22.6&nbsp;&nbsp;(3.8)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Medical Profession&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;55&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;50&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Medical Profession&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-9.5&nbsp;&nbsp;(2.9)&nbsp;   
                                                                        
                           </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-11.5&nbsp;&nbsp;(3.3)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Frustration with Treatment&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;48&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;48&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Frustration with Treatment&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-20.8&nbsp;&nbsp;(5.1)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-36.5&nbsp;&nbsp;(4.6)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Concerns with Infertility&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;47&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;48&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Concerns with Infertility&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-10.6&nbsp;&nbsp;(3.6)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-14.1&nbsp;&nbsp;(3.3)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                              <span class="header3">No statistical 
analysis provided for Change From Baseline to the End of the 
Double-blind Treatment Phase in Endometriosis Health Profile-5 (EHP-5)</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome26" id="outcome26"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">26.&nbsp; Secondary: &nbsp; </td>
            <td>Change From Baseline to the End of the Open-label 
Treatment Phase in Endometriosis Health Profile-5 (EHP-5) &nbsp; [ Time 
Frame: Baseline and week 24 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From Baseline to the End of the Open-label Treatment Phase in Endometriosis Health Profile-5 (EHP-5)</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">The
 EHP-5 is an instrument to measure health-related quality of life in 
women with endometriosis. The EHP-5 consists of two parts:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">A core questionnaire consisting of 
five questions that measure the impact of endometriosis on areas of 
pain, control and powerlessness, emotional well-being, social support, 
and self-image with five response categories for each item (Never, 
Rarely, Sometimes, Often, Always)</li>
    <li style="margin-top:0.7ex;">A supplemental questionnaire 
consisting of six additional questions which assess the impact of 
endometriosis on areas of work, relationship with children, sexual 
intercourse, feelings about the medical profession, treatment, and 
infertility with the same five response categories plus an additional 
response category of Not Relevant which was not scored.</li>
  </ul>
  <p style="margin-top:0ex; margin-bottom:1ex;">The scores associated 
with each possible outcome category are as follows: never (0), rarely 
(25), sometimes (50), often (75), and always (100). A negative change 
from baseline score indicates improvement in quality of life.</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and week 24 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 10 evaluable
 e-Diary reports during the double-blind period (intent-to-treat 
population) with data on or after Week 12. The analysis includes 
participants with non-missing data at baseline and week 24 for each 
question.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo orally once a 
day for 8 weeks during the double-blind treatment period and switched to
 receive 150 mg elagolix for 16 weeks during the open-label treatment 
period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received 150 mg elagolix orally 
once a day for 8 weeks during the double-blind treatment period and 
continued to receive 150 mg elagolix for 16 additional weeks during the 
open-label treatment period.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;61&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;60&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline to the End of the 
Open-label Treatment Phase in Endometriosis Health Profile-5 
(EHP-5)&nbsp;                        <br><span class="body3">[Units:&nbsp;Units&nbsp;on&nbsp;a&nbsp;scale]<br>Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Pain&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Pain&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-30.3&nbsp;&nbsp;(3.9)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-36.4&nbsp;&nbsp;(2.9)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Control and Powerlessness&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Control and Powerlessness&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-35.1&nbsp;&nbsp;(4.3)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-39.5&nbsp;&nbsp;(3.5)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Emotional Well-being&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Emotional Well-being&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-22.8&nbsp;&nbsp;(4.0)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-23.7&nbsp;&nbsp;(3.3)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Social Support&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Social Support&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-29.8&nbsp;&nbsp;(4.5)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-37.7&nbsp;&nbsp;(4.1)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Self-image&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;57&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Self-image&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-20.6&nbsp;&nbsp;(4.3)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-25.9&nbsp;&nbsp;(3.9)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Work&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;48&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;48&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Work&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-27.6&nbsp;&nbsp;(4.4)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-37.0&nbsp;&nbsp;(3.1)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Relationship with Children&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;24&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;20&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Relationship with Children&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-39.6&nbsp;&nbsp;(5.4)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-40.0&nbsp;&nbsp;(4.2)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Sexual Intercourse&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;49&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;46&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Sexual Intercourse&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-30.1&nbsp;&nbsp;(3.9)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-27.2&nbsp;&nbsp;(4.0)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Medical Profession&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;49&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;46&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Medical Profession&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-16.8&nbsp;&nbsp;(4.5)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-19.6&nbsp;&nbsp;(3.9)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Frustration with Treatment&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;45&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Frustration with Treatment&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-40.1&nbsp;&nbsp;(5.5)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-40.6&nbsp;&nbsp;(4.4)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Concerns with Infertility&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;42&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;45&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Concerns with Infertility&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-20.8&nbsp;&nbsp;(5.0)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-22.8&nbsp;&nbsp;(3.8)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                              <span class="header3">No statistical 
analysis provided for Change From Baseline to the End of the Open-label 
Treatment Phase in Endometriosis Health Profile-5 (EHP-5)</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome27" id="outcome27"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">27.&nbsp; Secondary: &nbsp; </td>
            <td>Percentage of Days With Uterine Bleeding During the 
Double- Blind Treatment Phase &nbsp; [ Time Frame: Screening (8 weeks 
prior to day 1) and the double-blind treatment phase (Weeks 1-8) ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Percentage of Days With Uterine Bleeding During the Double- Blind Treatment Phase</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">Uterine bleeding was reported daily by participants during the study using the e-Diary.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">The percentage of days a
 participant reported any bleeding was calculated as the total number of
 days the participant reported any bleeding ( light, moderate, or heavy)
 divided by the total number of days the participant had a non-missing 
e-Diary report of vaginal bleeding in the phase.</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Screening (8 weeks prior to day 1) and the double-blind treatment phase (Weeks 1-8) &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          Participants who received at 
least one dose of randomized, double-blind study drug (safety analysis 
set) with non-missing data.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo orally once a 
day for 8 weeks during the double-blind treatment period and switched to
 receive 150 mg elagolix for 16 weeks during the open-label treatment 
period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received 150 mg elagolix orally 
once a day for 8 weeks during the double-blind treatment period and 
continued to receive 150 mg elagolix for 16 additional weeks during the 
open-label treatment period.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;69&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;68&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Percentage of Days With Uterine Bleeding During 
the Double- Blind Treatment Phase&nbsp;                        <br><span class="body3">[Units:&nbsp;Percentage&nbsp;of&nbsp;days]<br>Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Screening&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;69&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;68&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Screening&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;24.29&nbsp;&nbsp;(0.96)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;22.98&nbsp;&nbsp;(1.12)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Double-Blind Treatment Phase (Weeks 1-8)&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;68&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;67&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Double-Blind Treatment Phase (Weeks 
1-8)&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;23.91&nbsp;&nbsp;(1.62)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;14.00&nbsp;&nbsp;(1.03)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                              <span class="header3">No statistical analysis provided for Percentage of Days With Uterine Bleeding During the Double- Blind Treatment Phase</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome28" id="outcome28"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">28.&nbsp; Secondary: &nbsp; </td>
            <td>Number of Days to First Posttreatment Menses &nbsp; [ 
Time Frame: From last day of study drug up to 6 weeks after the last 
dose. ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Number of Days to First Posttreatment Menses</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          Defined as the number of days 
from the last dose of study drug until the start date of the first 
post-treatment menses.
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">From last day of study drug up to 6 weeks after the last dose. &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          Participants who received at 
least one dose of randomized, double-blind study drug (safety analysis 
set) with non-missing post-treatment data.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo orally once a 
day for 8 weeks during the double-blind treatment period and switched to
 receive 150 mg elagolix for 16 weeks during the open-label treatment 
period.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received 150 mg elagolix orally 
once a day for 8 weeks during the double-blind treatment period and 
continued to receive 150 mg elagolix for 16 additional weeks during the 
open-label treatment period.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;56&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;58&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Number of Days to First Posttreatment Menses&nbsp;                        <br><span class="body3">[Units:&nbsp;Days]<br>Median (Full Range)</span>                       </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                                          &nbsp;22.0&nbsp;<br>
                                &nbsp;(1&nbsp;to&nbsp;40)&nbsp;
                                                                                    </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                                          &nbsp;25.0&nbsp;<br>
                                &nbsp;(3&nbsp;to&nbsp;45)&nbsp;
                                                                                    </td>
                                                                  </tr>
                    
                                                </tbody></table>
            
                            <br>


                              <span class="header3">No statistical analysis provided for Number of Days to First Posttreatment Menses</span>
                <br>

                            <br>
              <br>
                              </div>
          </div>
</div>
  
<!-- adverse events section -->
<br>
<div class="indent1">

  <br>
  <img src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20in%20Women%20With%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/triangle.gif" alt=""><span class="header2">&nbsp; Serious Adverse Events</span><br>
  <a name="evnt" id="evnt"></a>
  <div class="header3 indent2">

      <div style="margin-top:1.0ex;">
      <a title="Show serious adverse events" href="https://clinicaltrials.gov/ct2/show/results/NCT00973973?sect=X301256#evnt">
        <img style="float:left" src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20in%20Women%20With%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/plus.gif" alt="" border="0"> &nbsp; Show Serious Adverse Events
      </a>
    </div>
      </div>

  <br>
  <br>
  <img src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20in%20Women%20With%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/triangle.gif" alt=""><span class="header2">&nbsp; Other Adverse Events</span>
  <a name="othr" id="othr"></a>
  <div class="header3 indent2">

      <div style="margin-top:1.0ex;">
      <a title="Show other adverse events" href="https://clinicaltrials.gov/ct2/show/results/NCT00973973?sect=X401256#othr">
        <img style="float:left" src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20in%20Women%20With%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/plus.gif" alt="" border="0"> &nbsp; Show Other Adverse Events
      </a>
    </div>
      </div>
</div>
  
<!-- limitations and caveats section -->
<div class="indent1">

  <br>
  <br>
  <img src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20in%20Women%20With%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/triangle.gif" alt=""><span class="header2">&nbsp; Limitations and Caveats</span>

  <a name="limit" id="limit"></a>
  <div class="header3 indent2">

        <div style="margin-top:1.0ex;">
      <a title="Hide Limitations and Caveats" href="https://clinicaltrials.gov/ct2/show/results/NCT00973973?sect=X0126#limit">
        <img style="float:left" src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20in%20Women%20With%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/minus.gif" alt="" border="0"> &nbsp; Hide Limitations and Caveats
      </a>
    </div>

    <br>
    <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
      <tbody><tr>
        <th class="header3 bold_more_info_color" style="text-align:left;">
          Limitations of the study, such as early termination leading to small numbers of participants
          analyzed and technical problems with measurement leading to unreliable or uninterpretable data
        </th>
      </tr>
      <tr>
        <td class="body3 pale_more_info_color" style="vertical-align:top;">
                      No text entered.
                  </td>
      </tr>
    </tbody></table>

    </div>
</div>
  
<!-- more results info section -->
<br>
<div class="indent1">

  <br>
  <img src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20in%20Women%20With%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/triangle.gif" alt=""><span class="header2">&nbsp; More Information</span>
  <a name="more" id="more"></a>
  <div class="header3 indent2">

        <div style="margin-top:1.0ex;">
      <a title="Hide more information" href="https://clinicaltrials.gov/ct2/show/results/NCT00973973?sect=X0125#more">
        <img style="float:left" src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20in%20Women%20With%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/minus.gif" alt="" border="0"> &nbsp; Hide More Information
      </a>
    </div>

    <br>
    <div class="body3">

          <span class="header3">Certain Agreements: &nbsp; </span>
      <table class="layout_table" style="margin-top:0.5ex; border:1px solid #ccc;" width="100%" cellspacing="0" cellpadding="5">
              <tbody><tr>
          <td class="body3 pale_more_info_color">
                          Principal Investigators are <b>NOT</b> employed by the organization sponsoring the study.
                      </td>
        </tr>
      
              <tr>
          <td class="body3 pale_more_info_color">
                          There <b>IS</b> an agreement between Principal Investigators and the Sponsor (or its agents) that restricts
              the PI's rights to discuss or publish trial results after the trial is completed.
                      </td>
        </tr>
      
              <tr>
          <td class="body3 pale_more_info_color">
          The agreement is:<br>

          <table class="layout_table" cellspacing="0" cellpadding="5" border="0">
            <tbody><tr style="vertical-align:middle;">
              <td class="header1" style="white-space:nowrap;">
                <img src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20in%20Women%20With%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/uncheck.gif" alt="unchecked">              </td>
              <td class="body3">
                The only disclosure restriction on the PI is that the 
sponsor can review results communications prior to public release
                and can embargo communications regarding trial results 
for a period that is <b>less than or equal to 60 days</b>.
                The sponsor cannot require changes to the communication and cannot extend the embargo.
              </td>
            </tr>
            <tr style="vertical-align:middle;">
              <td class="header1" style="white-space:nowrap;">
                <img src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20in%20Women%20With%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/uncheck.gif" alt="unchecked">              </td>
              <td class="body3">
                The only disclosure restriction on the PI is that the 
sponsor can review results communications prior to public release
                and can embargo communications regarding trial results 
for a period that is <b>more than 60 days but less than
                or equal to 180 days</b>. The sponsor cannot require changes to the communication and cannot extend the embargo.
              </td>
            </tr>
            <tr class="banner_color" style="vertical-align:middle;">
              <td class="header1" nowrap="nowrap">
                <img src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20in%20Women%20With%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/check.gif" alt="checked">              </td>
              <td class="body3">
                Other disclosure agreement that restricts the right of 
the PI to discuss or publish trial results after the trial is completed.
                                  <br>
                  <br>
                  <span class="header3">Restriction Description:</span> 
&nbsp;
                                      AbbVie requests that any 
investigator or institution that plans on presenting/publishing results 
disclosure, provide written notification of their request 60 days prior 
to their presentation/publication. AbbVie requests that no 
presentation/publication will be instituted until 12 months after a 
study is completed, or after the first presentation/publication 
whichever occurs first. A delay may be proposed of a 
presentation/publication if AbbVie needs to secure patent or proprietary
 protection.
                                                </td>
            </tr>
          </tbody></table>
          </td>
        </tr>
            </tbody></table>
    
    <br>
          <br>
            <span class="header3">Results Point of Contact: &nbsp; </span>
      <div class="indent2" style="margin-top:1ex">
        Name/Title: Global Medical Services<br>
                  Organization: AbbVie<br>
                          phone: 800-633-9110<br>
                      </div>
      <br>
    
    <br>

    
    
    
    <br>
    <table class="layout_table" cellspacing="0" cellpadding="0" border="0">
            <tbody><tr style="vertical-align:top;">
        <td nowrap="nowrap">Responsible Party:</td>
        <td style="padding-left:1em">AbbVie</td>
      </tr>
            <tr style="vertical-align:top;">
        <td nowrap="nowrap">ClinicalTrials.gov Identifier:</td>
        <td style="padding-left:1em">
          <a title="Current version of study NCT00973973 on ClinicalTrials.gov" href="https://clinicaltrials.gov/show/NCT00973973">NCT00973973</a> &nbsp; &nbsp;
          <a href="https://clinicaltrials.gov/ct2/archive/NCT00973973" title="Historical versions of study NCT00973973 on ClinicalTrials.gov Archive Site" onclick="openNewWindow('/ct2/archive/NCT00973973'); return false;">History of Changes</a>
        </td>
      </tr>
                  <tr style="vertical-align:top;">
        <td headers="colTitle" nowrap="nowrap">Other Study ID Numbers:</td>
        <td headers="colData" style="padding-left:1em">
                                    NBI-56418-0901 <br>
                              </td>
      </tr>
      
            <tr style="vertical-align:top;">
        <td nowrap="nowrap">First Submitted:</td>
        <td style="padding-left:1em">September 7, 2009</td>
      </tr>
                  <tr style="vertical-align:top;">
        <td nowrap="nowrap">First Posted:</td>
        <td style="padding-left:1em">September 9, 2009</td>
      </tr>
                  <tr style="vertical-align:top;">
        <td nowrap="nowrap">Results First Submitted:</td>
        <td style="padding-left:1em">August 9, 2018</td>
      </tr>
                  <tr style="vertical-align:top;">
        <td nowrap="nowrap">Results First Posted:</td>
        <td style="padding-left:1em">September 26, 2018</td>
      </tr>
            <tr style="vertical-align:top;">
        <td nowrap="nowrap">Last Update Posted:</td>
        <td style="padding-left:1em">September 26, 2018
        </td>
      </tr>

    </tbody></table>

    </div>
    </div>
</div>

<br>
<br>
<br>
</div>
<div id="to-top"><a href="#wrapper">To Top</a></div>
</div>


	<div style="clear:both;"></div>
</div> 

<div>       <div id="for-footer">
        <ul class="horz-list">
            <li style="border-left:0;"><a href="https://clinicaltrials.gov/ct2/help/for-patient">For Patients and Families</a></li>
            <li><a href="https://clinicaltrials.gov/ct2/help/for-researcher">For Researchers</a></li>
            <li><a href="https://clinicaltrials.gov/ct2/help/for-manager">For Study Record Managers</a></li>
        </ul>
    </div>

</div>  
<div id="footer-menu">
    <ul class="horz-list" style="padding-bottom:1.5ex;">
		<li><a href="https://clinicaltrials.gov/ct2/home" style="white-space:nowrap">Home</a></li>
		<li><a href="https://clinicaltrials.gov/ct2/resources/rss" style="white-space:nowrap">RSS Feeds</a></li>
		<li><a href="https://clinicaltrials.gov/ct2/sitemap" style="white-space:nowrap">Site Map</a></li>
		<li><a href="https://clinicaltrials.gov/ct2/about-site/terms-conditions" style="white-space:nowrap">Terms and Conditions</a></li>
		<li><a href="https://clinicaltrials.gov/ct2/about-site/disclaimer" style="white-space:nowrap">Disclaimer</a></li>
		<li><a href="https://support.nlm.nih.gov/knowledgebase/category/?id=CAT-01242&amp;category=clinicaltrials.gov&amp;hd_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2Fresults%2FNCT00973973%3Fsect%3DX01256" style="white-space:nowrap" onclick="openNewWindow('https://support.nlm.nih.gov/knowledgebase/category/?id=CAT-01242&amp;category=clinicaltrials.gov&amp;hd_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2Fresults%2FNCT00973973%3Fsect%3DX01256'); return false">Customer Support</a></li>
	</ul>
</div>

</div>  
<div id="fine-print">
	<ul class="horz-list">
		<li><a title="NLM copyright information - opens new window" href="https://www.nlm.nih.gov/copyright.html" onclick="openNewWindow('https://www.nlm.nih.gov/copyright.html'); return false">Copyright</a></li>
		<li><a title="NLM privacy policy - opens new window" href="https://www.nlm.nih.gov/privacy.html" onclick="openNewWindow('https://www.nlm.nih.gov/privacy.html'); return false">Privacy</a></li>
		<li><a href="https://clinicaltrials.gov/ct2/accessibility" title="NLM Accessibility">Accessibility</a></li>
		<li><a title="NLM viewers and players - opens new window" href="https://www.nlm.nih.gov/plugins.html" onclick="openNewWindow('https://www.nlm.nih.gov/plugins.html'); return false">Viewers and Players</a></li>
		<li><a title="NIH Freedom of Information Act office - opens new window" href="https://www.nih.gov/icd/od/foia/index.htm" onclick="openNewWindow('https://www.nih.gov/icd/od/foia/index.htm'); return false">Freedom of Information Act</a></li>
		<li class="last-item"><a title="USA.gov - opens new window" href="https://www.usa.gov/" onclick="openNewWindow('https://www.usa.gov/'); return false">USA.gov</a></li>
	</ul>
    <ul class="horz-list">
       <li><a title="U.S. National Library of Medicine - opens new window" href="https://www.nlm.nih.gov/" onclick="openNewWindow('https://www.nlm.nih.gov/'); return false">U.S. National Library of Medicine</a></li>
       <li><a title="U.S. National Institutes of Health - opens new window" href="https://www.nih.gov/" onclick="openNewWindow('https://www.nih.gov/'); return false">U.S. National Institutes of Health</a></li>
       <li class="last-item"><a title="U.S. Department of Health and Human Services - opens new window" href="https://www.hhs.gov/" onclick="openNewWindow('https://www.hhs.gov/'); return false">
            U.S. Department of Health and Human Services</a></li>
    </ul>
</div>

<script type="text/javascript">__ncbi_sg_gaMode="clinicaltrials"</script>
<script type="text/javascript" src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20in%20Women%20With%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/instrumentNCBIBaseJS.js"></script><script async="1" src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20in%20Women%20With%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/analytics.js"></script><noscript></noscript>
<script type="text/javascript" src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20in%20Women%20With%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/main-glossary.js"></script><noscript></noscript>



<ul class="print-log"><li></li></ul></body></html>